Cover
Cover - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Feb. 19, 2021 | Jun. 30, 2020 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Entity File Number | 001-38796 | ||
Entity Registrant Name | GOSSAMER BIO, INC. | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 47-5461709 | ||
Entity Address, Address Line One | 3013 Science Park Road | ||
Entity Address, City or Town | San Diego | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 92121 | ||
City Area Code | 858 | ||
Local Phone Number | 684-1300 | ||
Title of 12(b) Security | Common Stock, $0.0001 par value per share | ||
Trading Symbol | GOSS | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Small Business | false | ||
Entity Emerging Growth Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Entity Shell Company | false | ||
Entity Public Float | $ 774.8 | ||
Entity Common Stock, Shares Outstanding | 75,527,707 | ||
Documents Incorporated by Reference | DOCUMENTS INCORPORATED BY REFERENCE Certain sections of the registrant’s definitive proxy statement for the 2021 annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after end of this fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K. | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2020 | ||
Document Fiscal Year Focus | 2020 | ||
Document Fiscal Period Focus | FY | ||
Entity Central Index Key | 0001728117 | ||
Current Fiscal Year End Date | --12-31 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Current assets | ||
Cash and cash equivalents | $ 486,055 | $ 135,026 |
Marketable securities | 26,573 | 266,740 |
Restricted cash | 565 | 63 |
Prepaid expenses and other current assets | 9,129 | 7,488 |
Total current assets | 522,322 | 409,317 |
Property and equipment, net | 5,534 | 5,425 |
Operating lease right-of-use assets | 10,550 | 10,303 |
Other assets | 1,027 | 1,559 |
Total assets | 539,433 | 426,604 |
Current liabilities | ||
Accounts payable | 7,508 | 956 |
Accrued research and development expenses | 10,431 | 19,258 |
Accrued expenses and other current liabilities | 20,711 | 16,709 |
Total current liabilities | 38,650 | 36,923 |
Long-term convertible senior notes | 143,642 | 0 |
Long-term debt | 28,744 | 28,459 |
Operating lease liabilities - long-term | 7,713 | 8,737 |
Total liabilities | 218,749 | 74,119 |
Commitments and contingencies | ||
Stockholders' equity (deficit) | ||
Common stock, $0.0001 par value; 700,000,000 shares authorized as of December 31, 2020 and December 31, 2019; 75,524,254 shares issued and 73,874,904 shares outstanding as of December 31, 2020, and 66,284,003 shares issued and 61,635,477 shares outstanding as of December 31, 2019 | 8 | 7 |
Additional paid-in capital | 897,607 | 686,390 |
Accumulated deficit | (577,530) | (334,170) |
Accumulated other comprehensive income | 599 | 258 |
Total stockholders' equity | 320,684 | 352,485 |
Total liabilities and stockholders' equity | $ 539,433 | $ 426,604 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2020 | Dec. 31, 2019 |
Statement of Financial Position [Abstract] | ||
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 700,000,000 | 700,000,000 |
Common stock, shares issued (in shares) | 75,524,254 | 66,284,003 |
Common stock, shares outstanding (in shares) | 73,874,904 | 61,635,477 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Operating expenses: | |||
Research and development | $ 160,854 | $ 143,403 | $ 55,283 |
In process research and development | 23,380 | 3,600 | 49,659 |
General and administrative | 49,728 | 39,136 | 44,051 |
Total operating expenses | 233,962 | 186,139 | 148,993 |
Loss from operations | (233,962) | (186,139) | (148,993) |
Other income (expense) | |||
Interest income | 3,442 | 5,563 | 1,720 |
Interest expense | (12,666) | (1,938) | (12) |
Other income (expense) | (174) | 2,207 | 316 |
Total other income (expense), net | (9,398) | 5,832 | 2,024 |
Net loss | (243,360) | (180,307) | (146,969) |
Other comprehensive income: | |||
Foreign currency translation, net of tax | 441 | (12) | 0 |
Unrealized gain (loss) on marketable securities, net of tax | (100) | 331 | (61) |
Other comprehensive income (loss) | 341 | 319 | (61) |
Comprehensive loss | $ (243,019) | $ (179,988) | $ (147,030) |
Net loss per share, basic and diluted (in dollars per share) | $ (3.55) | $ (3.29) | $ (22.59) |
Weighted average common shares outstanding, basic and diluted (in shares) | 68,510,260 | 54,740,170 | 6,504,871 |
Consolidated Statements of Conv
Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands | Total | Common stock | Additional paid-in capital | Accumulated deficit | Accumulated other comprehensive income (loss) | Series Seed convertible preferred stock | Series A convertible preferred stock | Series B convertible preferred stock |
Convertible preferred stock, beginning balance (in shares) at Dec. 31, 2017 | 0 | 0 | 0 | |||||
Convertible preferred stock, beginning balance at Dec. 31, 2017 | $ 0 | $ 0 | $ 0 | |||||
Increase (Decrease) in Temporary Equity [Roll Forward] | ||||||||
Issuance of preferred stock for cash, net of offering costs (in shares) | 42,215,077 | 71,506,513 | ||||||
Issuance of preferred stock for cash, net of offering costs | $ 73,491 | $ 229,552 | ||||||
Issuance of stock for acquisition (in shares) | 20,000,000 | |||||||
Issuance of stock for acquisition | $ 29,200 | |||||||
Issuance of Series A preferred stock to convert debt and accrued interest (in shares) | 3,499,209 | |||||||
Issuance of Series A preferred stock to convert debt and accrued interest | $ 6,124 | |||||||
Convertible preferred stock, ending balance (in shares) at Dec. 31, 2018 | 20,000,000 | 45,714,286 | 71,506,513 | |||||
Convertible preferred stock, ending balance at Dec. 31, 2018 | $ 29,200 | $ 79,615 | $ 229,552 | |||||
Beginning balance (in shares) at Dec. 31, 2017 | 9,160,888 | |||||||
Beginning balance at Dec. 31, 2017 | $ (6,862) | $ 0 | $ 32 | $ (6,894) | $ 0 | |||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Vesting of restricted stock (in shares) | 2,369,696 | |||||||
Vesting of restricted stock | $ 1 | $ 1 | ||||||
Exercise of stock options (in shares) | 0 | |||||||
Stock-based compensation | $ 30,947 | 30,947 | ||||||
Issuance of stock for acquisition (in shares) | 1,101,278 | |||||||
Conversion of convertible preferred stock into common stock | 2,875 | $ 1 | 2,874 | |||||
Incremental vesting conditions placed on previously issued common shares (in shares) | (4,580,444) | |||||||
Net loss | (146,969) | (146,969) | ||||||
Other comprehensive income (loss) | (61) | (61) | ||||||
Ending balance (in shares) at Dec. 31, 2018 | 8,051,418 | |||||||
Ending balance at Dec. 31, 2018 | (120,069) | $ 2 | 33,853 | (153,863) | (61) | |||
Increase (Decrease) in Temporary Equity [Roll Forward] | ||||||||
Conversion of convertible preferred stock into common stock (in shares) | (20,000,000) | (45,714,286) | (71,506,513) | |||||
Temporary Equity Issued During Period Value Conversion Of Convertible Securities | $ (29,200) | $ (79,615) | $ (229,552) | |||||
Convertible preferred stock, ending balance (in shares) at Dec. 31, 2019 | 0 | 0 | 0 | |||||
Convertible preferred stock, ending balance at Dec. 31, 2019 | $ 0 | $ 0 | $ 0 | |||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Issuance of common stock in connection with a public offering, net of underwriting discounts, commissions, and offering costs (in shares) | 19,837,500 | |||||||
Issuance of common stock in connection with a public offering, net of underwriting discounts, commissions, and offering costs | $ 291,311 | $ 2 | 291,309 | |||||
Vesting of restricted stock (in shares) | 2,833,506 | |||||||
Exercise of stock options (in shares) | 419,593 | 419,593 | ||||||
Exercise of stock options | $ 2,045 | 2,045 | ||||||
Stock-based compensation | 20,819 | 20,819 | ||||||
Conversion of convertible preferred stock into common stock (in shares) | 30,493,460 | |||||||
Conversion of convertible preferred stock into common stock | 338,367 | $ 3 | 338,364 | |||||
Net loss | (180,307) | (180,307) | ||||||
Other comprehensive income (loss) | 319 | 319 | ||||||
Ending balance (in shares) at Dec. 31, 2019 | 61,635,477 | |||||||
Ending balance at Dec. 31, 2019 | 352,485 | $ 7 | 686,390 | (334,170) | 258 | |||
Convertible preferred stock, ending balance (in shares) at Dec. 31, 2020 | 0 | 0 | 0 | |||||
Convertible preferred stock, ending balance at Dec. 31, 2020 | $ 0 | $ 0 | $ 0 | |||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Issuance of common stock in connection with a public offering, net of underwriting discounts, commissions, and offering costs (in shares) | 9,433,963 | |||||||
Issuance of common stock in connection with a public offering, net of underwriting discounts, commissions, and offering costs | 117,094 | $ 1 | 117,093 | |||||
Equity component of convertible note issuance | 53,635 | 53,635 | ||||||
Debt issuance costs attributable to convertible feature | $ (109) | (109) | ||||||
Vesting of restricted stock (in shares) | 2,557,375 | |||||||
Exercise of stock options (in shares) | 134,803 | 134,803 | ||||||
Exercise of stock options | $ 534 | 534 | ||||||
Stock-based compensation | 38,748 | 38,748 | ||||||
Issuance of common stock pursuant to Employee Stock Purchase Plan (in shares) | 113,286 | |||||||
Issuance of common stock pursuant to Employee Stock Purchase Plan | 1,300 | 1,300 | ||||||
Other additional paid-in capital | 16 | 16 | ||||||
Net loss | (243,360) | (243,360) | ||||||
Other comprehensive income (loss) | 341 | 341 | ||||||
Ending balance (in shares) at Dec. 31, 2020 | 73,874,904 | |||||||
Ending balance at Dec. 31, 2020 | $ 320,684 | $ 8 | $ 897,607 | $ (577,530) | $ 599 |
Consolidated Statements of Co_2
Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) $ in Millions | 12 Months Ended |
Dec. 31, 2018USD ($) | |
Series A convertible preferred stock | |
Issuance of shares, offering costs | $ 0.4 |
Series B convertible preferred stock | |
Issuance of shares, offering costs | $ 0.5 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Cash flows from operating activities | |||
Net loss | $ (243,360) | $ (180,307) | $ (146,969) |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Depreciation and amortization | 1,409 | 917 | 297 |
Stock-based compensation expense | 38,748 | 20,819 | 30,947 |
In process research and development expenses | 23,380 | 3,600 | 49,659 |
Amortization of operating lease right-of-use assets | 2,859 | 2,172 | 0 |
Amortization of long-term debt discount and issuance costs | 3,857 | 237 | 0 |
Amortization of premium on investments, net of accretion of discounts | 98 | (2,364) | 0 |
Net realized gain on investments | (256) | (28) | 0 |
Changes in operating assets and liabilities: | |||
Prepaid expenses and other current assets | (1,641) | (4,393) | (2,827) |
Other assets | 532 | 2,714 | (584) |
Operating lease liabilities | (2,851) | (2,108) | 0 |
Accounts payable | 6,984 | (1,399) | 2,085 |
Accrued expenses | 1,096 | 1,521 | 5,938 |
Accrued research and development expenses | (8,827) | 8,605 | 10,527 |
Accrued compensation and benefits | 1,612 | 5,180 | 0 |
Accrued interest expense | 0 | 0 | (117) |
Net cash used in operating activities | (176,360) | (144,834) | (51,044) |
Cash flows from investing activities | |||
Research and development asset acquisitions, net of cash acquired | (23,380) | (3,600) | (17,721) |
Purchase of marketable securities | (108,968) | (499,079) | (123,500) |
Maturities of marketable securities | 265,678 | 328,000 | 0 |
Sales of marketable securities | 83,515 | 30,501 | 0 |
Purchase of property and equipment | (1,503) | (2,966) | (3,490) |
Net cash provided by (used in) investing activities | 215,342 | (147,144) | (144,711) |
Cash flows from financing activities | |||
Proceeds from issuance of common stock | 117,110 | 291,311 | 0 |
Proceeds from issuance of convertible senior notes, net | 193,596 | 0 | 0 |
Proceeds from the issuance of long-term debt, net of debt discount and issuance costs $1,778 | 0 | 28,222 | 0 |
Proceeds from the exercise of stock options | 534 | 2,045 | 0 |
Repayment of notes payable to related parties | 0 | 0 | (40) |
Payment of deferred offering costs | 0 | 0 | (2,144) |
Net cash provided by financing activities | 312,540 | 321,578 | 300,859 |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | 9 | 70 | 0 |
Net increase in cash, cash equivalents and restricted cash | 351,531 | 29,670 | 105,104 |
Cash, cash equivalents and restricted cash, at the beginning of the period | 135,089 | 105,419 | 315 |
Cash, cash equivalents and restricted cash, at the end of the period | 486,620 | 135,089 | 105,419 |
Supplemental disclosure of cash flow information: | |||
Cash paid for interest | 7,871 | 1,475 | 119 |
Supplemental disclosure of noncash investing and financing activities: | |||
Acquisition of in-process research and development through issuance of stock | 0 | 0 | 19,284 |
Issuance of Series A convertible preferred stock to convert debt and accrued interest | 0 | 0 | 6,124 |
Unpaid deferred offering costs - net | 0 | 0 | 1,545 |
Right-of-use assets obtained in exchange for lease liabilities | 3,106 | 12,458 | 0 |
Conversion of convertible preferred stock to common stock | 0 | 338,367 | 0 |
Change in unrealized gain (loss) on marketable securities, net of tax | (100) | 331 | (61) |
Unpaid property and equipment | 15 | 183 | 0 |
2019 Employee Stock Purchase Plan | |||
Cash flows from financing activities | |||
Proceeds from issuance of common stock | 1,300 | 0 | 0 |
Series A convertible preferred stock | |||
Cash flows from financing activities | |||
Proceeds from issuance of convertible preferred stock, net | 0 | 0 | 73,491 |
Series B convertible preferred stock | |||
Cash flows from financing activities | |||
Proceeds from issuance of convertible preferred stock, net | $ 0 | $ 0 | $ 229,552 |
Consolidated Statements of Ca_2
Consolidated Statements of Cash Flows (Parenthetical) $ in Thousands | 12 Months Ended |
Dec. 31, 2019USD ($) | |
Statement of Cash Flows [Abstract] | |
Debt issuance costs | $ 1,778 |
Organization and Basis of Prese
Organization and Basis of Presentation | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Organization and Basis of Presentation | Organization and Basis of Presentation Gossamer Bio, Inc. (including its subsidiaries, the “Company”) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company was incorporated in the state of Delaware on October 25, 2015 (originally as FSG Bio, Inc.) and is based in San Diego, California. The consolidated financial statements include the accounts of Gossamer Bio, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. Initial Public Offering in February 2019 On February 12, 2019, the Company completed its initial public offering (“IPO”) with the sale of 19,837,500 shares of common stock, including shares of common stock issued upon the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $16.00 per share, resulting in net proceeds of $291.3 million after deducting underwriting discounts, commissions, and offering expenses. Liquidity and Capital Resources The Company has incurred significant operating losses since its inception. As of December 31, 2020 and 2019, the Company had an accumulated deficit of $577.5 million and $334.2 million, respectively. From the Company’s inception through the year ended December 31, 2020, the Company has funded its operations primarily through equity financings and debt issuance. The Company raised $942.0 million from October 2017 through December 31, 2020 through Series A and Series B convertible preferred stock financings, a convertible note financing, its IPO, its Credit Facility (as defined in Note 5 below), and concurrent underwritten public offerings of its 5.00% convertible senior notes due 2027 (the "2027 Notes") and common stock in May 2020. See Note 5 for additional information regarding the Credit Facility and the 2027 Notes. In addition, the Company received $12.8 million in cash in connection with the January 2018 acquisition of AA Biopharma Inc. The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As a result, the Company will need to raise capital through equity offerings, debt financings and other capital sources, including potential collaborations, licenses and other similar arrangements. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company’s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years. COVID-19 The COVID-19 pandemic has caused significant business disruption around the globe. The extent of the impact of COVID-19 on the Company’s operational and financial performance will depend on certain developments, including the duration and spread of the pandemic and the impact on the Company’s clinical trials, employees and vendors. At this point, the degree to which COVID-19 has impacted and may continue to impact the Company’s financial condition or results of operations is uncertain. A prolonged pandemic could have a material and adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its product candidates and raise additional capital. For example, the Company temporarily paused enrollment in its Phase 1b clinical trial in pulmonary arterial hypertension ("PAH") in 2020 as a result of the ongoing COVID-19 pandemic. In addition, due to the challenges of enrolling patients posed by the COVID-19 pandemic, the Company may experience delays in enrollment of patients in its Phase 2 clinical trials of GB004 in ulcerative colitis and of seralutinib, also known as GB002, in PAH, as well as delays in reporting data results from its ongoing trials. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Certain prior period amounts have been reclassified to conform to the current period presentation. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s consolidated financial statements relate to the allocation of the 2027 Notes into liability and equity components and accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates. Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. Marketable Securities The Company considers securities with original maturities of greater than 90 days to be marketable securities. The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as current assets on the accompanying condensed consolidated balance sheets. The Company’s marketable securities consist of U.S. Treasury and agency securities, commercial paper, and corporate debt securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded as interest income or expense. The Company does not generally intend to sell the investments and it is not more likely than not that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The Company has determined that there were no material declines in fair values of its investments due to credit-related factors as of December 31, 2020. Restricted Cash Restricted cash as of December 31, 2020, and 2019 represents cash held as collateral for the Company's facility leases. Restricted cash as of December 31, 2018 served as collateral for the Company’s corporate credit card program. Concentrations of Credit Risk and Off-Balance Sheet Risk Cash, cash equivalents and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in U.S. Treasury and agency securities and commercial paper with maturities less than three months and in money market funds that invest in U.S. Treasury and agency securities. The Company’s available for sale securities are also invested in U.S. Treasury and agency securities. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents and available for sale securities. Property and Equipment, Net Property and equipment, net, which consists mainly of office equipment and leasehold improvements, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally three to seven years, using the straight-line method. Convertible Senior Notes In accounting for the issuance of the 2027 Notes, the Company separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments that do not have associated convertible features. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes. The equity component is not remeasured as long as it continues to meet the condition for equity classification. The excess of the principal amount of the liability component over its carrying amount (“debt discount”) is amortized to interest expense over the term of the 2027 Notes. The Company allocated the issuance costs incurred to the liability and equity components of the 2027 Notes based on their relative fair values. Issuance costs attributable to the liability component were recorded as a reduction to the liability portion of the 2027 Notes and are being amortized to interest expense over the term of the 2027 Notes. Issuance costs attributable to the equity component, representing the conversion option, were netted with the equity component in stockholders' equity. Leases In accordance with Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), as adopted on January 1, 2019, the Company determines if an arrangement is a lease at inception. Operating leases are included in the balance sheet as right-of-use assets and operating lease liabilities at the present value of the lease payments calculated using the Company’s incremental borrowing rate, unless the implicit rate is readily available. The Company applied the short-term lease recognition exemption for leases with terms at inception not greater than 12 months and elected to not separate lease and non-lease components for its long-term leases. The Company records rent expense on a straight-line basis over the term of the lease. Research and Development All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services) and in process research and development expenses. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractor’s bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial. Upfront costs, such as costs associated with setting up clinical trial sites for participation in the trials, are expensed immediately once incurred as research and development expenses. Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses. Income Taxes Income taxes are recorded in accordance with Financial Accounting Standards Board (“FASB”) Standards Codification (“ASC”) No. 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. Deferred tax assets and liabilities reflect the future tax consequences of the differences between the financial reporting and tax bases of assets and liabilities using current enacted tax rates. Valuation allowances are recorded when the realizability of such deferred tax assets does not meet a more-likely-than-not threshold. For tax benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company is subject to taxation in the United States and California, Ireland and Luxembourg. As of December 31, 2020, the Company’s tax years since inception are subject to examination by taxing authorities due to the Company’s unutilized net operating losses ("NOLs") and tax credits. Stock-Based Compensation The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the requisite service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants and shares purchasable under the Company's 2019 Employee Stock Purchase Plan ("ESPP") using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company estimates the fair value of restricted stock units based on the closing price of the Company's common stock on the date of grant. The Company accounts for forfeitures as they occur. All share-based compensation costs are recorded in the statements of operations based upon the underlying employees or non-employee’s roles within the Company. Foreign Currency Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where that local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense accounts are translated at average exchange rates during the year which approximate the rates in effect at the transaction dates. The resulting translation adjustments are recorded in accumulated other comprehensive income (loss). Foreign exchange transaction gains and losses are included in other income (expense) in the Company’s consolidated statement of operations and comprehensive loss. Recent Accounting Pronouncements—To Be Adopted In August 2020, the FASB issued ASU 2020-06, Debt: Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40) (“ASU 2020-06”), which simplifies the accounting for convertible instruments and contracts in an entity's own equity. This guidance is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those years, with early adoption permitted only as of annual reporting periods beginning after December 15, 2020. The Company is currently assessing the impact this standard will have on its consolidated financial statements or related financial statement disclosures. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which changes the impairment model for most financial assets and certain other instruments. For trade receivables and other instruments, entities will be required to use a new forward-looking expected loss model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. This guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those years, with early adoption permitted only as of annual reporting periods beginning after December 15, 2018. The Company adopted ASU 2016-13 as of January 1, 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements or related financial statement disclosures. Net Loss Per Share Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The Company uses the if-converted method for assumed conversion of the 2027 Notes to compute the weighted average shares of common stock outstanding for diluted net loss per share. Diluted net loss per share excludes the potential impact of the Company's Series Seed convertible preferred stock, Series A convertible preferred stock, and Series B convertible preferred stock, common stock options and unvested shares of restricted stock and the potential shares issuable upon conversion of the 2027 Notes because their effect would be anti-dilutive due to the Company’s net loss. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same. The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive: December 31, 2020 2019 2018 Shares issuable upon conversion of Series Seed convertible preferred stock — — 4,444,444 Shares issuable upon conversion of Series A convertible preferred stock — — 10,158,710 Shares issuable upon conversion of Series B convertible preferred stock — — 15,890,306 2027 Notes 12,321,900 — — Shares issuable upon exercise of stock options 9,401,082 8,538,060 5,107,329 Non-vested shares under restricted stock grants 3,330,821 4,648,526 7,482,032 |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 12 Months Ended |
Dec. 31, 2020 | |
Payables and Accruals [Abstract] | |
Accrued Expenses and Other Current Liabilities | Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): Years Ended December 31, 2020 2019 Accrued compensation $ 12,194 $ 9,282 Operating lease liabilities, current 3,633 2,354 Accrued consulting fees 1,919 1,337 Accrued interest, current 1,094 — Accrued other 742 1,126 Accrued legal fees 619 837 Accrued accounting fees 285 173 Accrued in process research and development 225 1,600 Total accrued expenses $ 20,711 $ 16,709 |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company classifies its cash equivalents and available-for-sale investments within Level 1 or Level 2. The fair value of the Company’s investment grade corporate debt securities and commercial paper is determined using proprietary valuation models and analytical tools, which utilize market pricing or prices for similar instruments that are both objective and publicly available, such as matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, and offers. Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table presents the hierarchy for assets measured at fair value on a recurring basis as of December 31, 2020 and December 31, 2019 (in thousands): Fair Value Measurements at End of Period Using: Total Quoted Market Significant Significant As of December 31, 2020 Money market funds $ 411,104 $ 411,104 $ — $ — U.S. Treasury and agency securities 18,280 18,280 — — Corporate debt securities 26,573 — 26,573 — As of December 31, 2019 Money market funds $ 82,125 $ 82,125 $ — $ — U.S. Treasury and agency securities 91,717 91,717 — — Commercial paper 37,411 — 37,411 — Corporate debt securities 156,277 — 156,277 — The Company did not reclassify any investments between levels in the fair value hierarchy during the periods presented. Fair Value of Other Financial Instruments As of December 31, 2020 and December 31, 2019, the carrying amounts of the Company’s financial instruments, which include cash, interest receivable, accounts payable and accrued expenses, approximate fair values because of their short maturities. Interest receivable as of December 31, 2020 and December 31, 2019 was $0.2 million and $1.5 million, respectively, and is recorded as a component of prepaid expenses and other current assets on the condensed consolidated balance sheets. The Company believes that its Credit Facility bears interest at a rate that approximates prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value of the Credit Facility approximates fair value. The Company estimates the fair value of long-term debt utilizing an income approach. The Company uses a present value calculation to discount principal and interest payments and the final maturity payment on these liabilities using a discounted cash flow model based on observable inputs. The debt instrument is then discounted based on what the current market rates would be as of the reporting date. Based on the assumptions used to value these liabilities at fair value, the debt instrument is categorized as Level 2 in the fair value hierarchy. As of December 31, 2020 the fair value of the Company's 2027 Notes was $198.5 million. The fair value was determined on the basis of market prices observable for similar instruments and is considered Level 2 in the fair value hierarchy (see Note 5). Available for Sale Investments The Company invests its excess cash in U.S. Treasury and agency securities and debt instruments of corporations and commercial obligations, which are classified as available-for-sale investments. These investments are carried at fair value and are included in the tables below. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded as interest income or expense. The Company does not generally intend to sell the investments and it is not more likely than not that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in marketable securities and long-term investments as of December 31, 2020 are as follows (in thousands): Amortized Gross Gross Total Marketable securities Corporate debt securities $ 26,396 $ 177 $ — $ 26,573 Total marketable securities $ 26,396 $ 177 $ — $ 26,573 As of December 31, 2020 and 2019, the Company classified $18.3 million and $18.7 million, respectively, of assets with original maturities of 90 days or less as cash equivalents. At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Factors considered when evaluating available-for-sale investments for impairment include the severity of the impairment, changes in underlying credit ratings, the financial condition of the issuer, the probability that the scheduled cash payments will continue to be made and the Company’s intent and ability to hold the investment until recovery of the amortized cost basis. The Company intends and has the ability to hold its investments in unrealized loss positions until their amortized cost basis has been recovered. As of December 31, 2020, there were no material declines in the market value of the Company's available-for-sale investments due to credit-related factors. Contractual maturities of available-for-sale debt securities, as of December 31, 2020, were as follows (in thousands): Estimated Due within one year $ 26,573 One to two years — Total $ 26,573 |
Indebtedness
Indebtedness | 12 Months Ended |
Dec. 31, 2020 | |
Debt Disclosure [Abstract] | |
Indebtedness | Indebtedness Credit Facility On May 2, 2019, the Company entered into a credit, guaranty and security agreement, as amended on September 18, 2019 and July 2, 2020 (the “Credit Facility”), with MidCap Financial Trust (“MidCap”), as agent and lender, and the additional lenders party thereto from time to time (together with MidCap, the “Lenders”), pursuant to which the Lenders, including affiliates of MidCap and Silicon Valley Bank, agreed to make term loans available to the Company for working capital and general business purposes, in a principal amount of up to $150.0 million in term loan commitments, including a $30.0 million term loan that was funded at the closing date, with the ability to access the remaining $120.0 million in two additional tranches (each $60.0 million), subject to specified availability periods, the achievement of certain clinical development milestones, minimum cash requirements and other customary conditions. The Company, GB001, Inc., GB002, Inc., and GB004, Inc., each wholly-owned subsidiaries of the Company, are designated as co-borrowers to the Credit Facility, whereas GB003, Inc., GB005, Inc., GB006, Inc., GB007, Inc., GB008, Inc., and Gossamer Bio Services, Inc.,each wholly-owned subsidiaries of the Company, are designated as guarantors. The remaining two tranches are available no earlier than the satisfaction of the applicable funding conditions, including the applicable clinical development milestones, and no later than December 31, 2022. As of December 31, 2020, no other tranches under the Credit Facility have been available. The Credit Facility is secured by substantially all of the Company’s and its domestic subsidiaries’ personal property, including intellectual property. Each term loan under the Credit Facility bears interest at an annual rate equal to the sum of (i) one-month LIBOR (customarily defined, with a change to prime rate if LIBOR funding becomes unlawful or impractical) plus (ii) 7.00%, subject to a LIBOR floor of 2.00%. The Company is required to make interest-only payments on the term loan for all payment dates prior to July 1, 2022. The term loans under the Credit Facility will begin amortizing on July 1, 2022, with equal monthly payments of principal plus interest being made by the Company to the Lenders in consecutive monthly installments following such interest-only period until the Credit Facility matures on January 1, 2025. Upon final repayment of the term loans, the Company must pay an exit fee of 1.75% of the amount borrowed under the Credit Facility, less any partial exit fees previously paid. Upon partial prepayment of a portion of the term loans, the Company must pay a partial exit fee of 1.75% of the principal being prepaid. At the Company’s option, the Company may prepay the outstanding principal balance of the term loan in whole or in part, subject to a prepayment fee of 3.00% of any amount prepaid if the prepayment occurs through and including the first anniversary of the second amendment effective date, 2.00% of the amount prepaid if the prepayment occurs after the first anniversary of the second amendment effective date through and including the second anniversary of the second amendment effective date, and 1.00% of any amount prepaid after the second anniversary of the second amendment effective date and prior to January 1, 2025. The Credit Facility includes affirmative and negative covenants applicable to the Company and certain of its subsidiaries. The affirmative covenants include, among others, covenants requiring such entities to maintain their legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage, maintain property, pay taxes, satisfy certain requirements regarding accounts and comply with laws and regulations. The negative covenants include, among others, restrictions on such entities from transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, amending material agreements and organizational documents, selling assets and suffering a change in control, in each case subject to certain exceptions. The Company and certain of its subsidiaries are also subject to an ongoing minimum cash financial covenant in which they must maintain unrestricted cash in an amount not less than 25% of the outstanding principal amount of the term loans. As of December 31, 2020, the Company was in compliance with these covenants. The Credit Facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 3.00% and would provide MidCap, as agent, with the right to exercise remedies against the Company and/or certain of its subsidiaries, and the collateral securing the Credit Facility, including foreclosure against the properties securing the credit facilities, including cash. These events of default include, among other things, failure to pay any amounts due under the Credit Facility, a breach of covenants under the Credit Facility, insolvency or the occurrence of insolvency events, the occurrence of a change in control, the occurrence of certain U.S. Food and Drug Administration ("FDA") and regulatory events, failure to remain registered with the SEC and listed for trading on Nasdaq, the occurrence of a material adverse change, the occurrence of a default under a material agreement reasonably expected to result in a material adverse change, the occurrence of certain defaults under certain other indebtedness in an amount greater than $2.5 million and the occurrence of certain defaults under subordinated indebtedness and convertible indebtedness. Long-term debt as of December 31, 2020 consisted of the following (in thousands): December 31, 2020 Term loan $ 30,000 Debt discount and issuance costs (1,256) Long-term debt $ 28,744 The scheduled future minimum principal payments are as follows (in thousands): December 31, 2020 2021 — 2022 5,806 2023 11,613 2024 11,613 2025 968 Total $ 30,000 5.00% Convertible Senior Notes due 2027 On May 21, 2020, the Company issued $200.0 million aggregate principal amount of 5.00% convertible senior notes due 2027 in a public offering. The 2027 Notes were registered pursuant to the Company’s Shelf Registration Statement (as defined in Note 8 below). The interest rate on the 2027 Notes is fixed at 5.00% per annum. Interest is payable semi-annually in arrears on June 1 and December 1 of each year, commencing on December 1, 2020. The 2027 Notes will mature on June 1, 2027. The net proceeds from the offering, after deducting the underwriting discounts and commissions and other offering costs, were approximately $193.6 million. The 2027 Notes may be settled in cash, shares of the Company’s common stock, or a combination thereof, solely at the Company’s election. The initial conversion rate of the 2027 Notes is 61.6095 shares per $1,000 principal amount, which is equivalent to a conversion price of approximately $16.23 per share, subject to adjustments. In addition, following certain corporate events that occur prior to the maturity date or if the Company issues a notice of redemption, the Company will increase the conversion rate for a holder who elects to convert its 2027 Notes in connection with such a corporate event during the related redemption period in certain circumstances. The 2027 Notes are senior unsecured obligations of the Company, ranking senior in right of payment to any of the Company’s indebtedness that is expressly subordinated in right of payment to the 2027 Notes, and are effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness, including all indebtedness under the Credit Facility. Holders may convert their notes at their option only in the following circumstances: (1) during any calendar quarter (and only during such calendar quarter) commencing after the calendar quarter ending on September 30, 2020, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price for each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the “measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company’s common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company’s common stock; (4) if the Company calls such notes for redemption; and (5) at any time from, and including, March 1, 2027 until the close of business on the scheduled trading day immediately before the maturity date. The Company will not have the right to redeem the 2027 Notes prior to June 6, 2024. On or after June 6, 2024 and on or before the 50th scheduled trading day immediately before the maturity date, the Company may redeem the 2027 Notes, in whole or in part, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect on (1) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (2) the trading day immediately before the date the Company sends such notice. In the case of any optional redemption, the Company will redeem the 2027 Notes at a redemption price equal to 100% of the principal amount of such Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If the Company undergoes a fundamental change prior to the maturity date of the 2027 Notes, holders of the 2027 Notes may require the Company to repurchase for cash all or part of their 2027 Notes at a repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The indenture governing the 2027 Notes provides for customary terms and covenants, including that upon certain events of default, either the trustee or the holders of not less than 25% in aggregate principal amount of the 2027 Notes then outstanding may declare the unpaid principal amount of the 2027 Notes and accrued and unpaid interest, if any, thereon immediately due and payable. As of December 31, 2020, the Company was in compliance with these covenants. In the case of certain events of bankruptcy, insolvency or reorganization, the principal amount of the 2027 Notes together with accrued and unpaid interest, if any, thereon will automatically become and be immediately due and payable. As of December 31, 2020, there were no events or market conditions that would allow holders to convert the 2027 Notes. At the time the 2027 Notes become convertible within 12 months of the balance sheet date, the carrying value of the 2027 Notes will be reclassified to short-term. In accounting for the issuance of the 2027 Notes, the Company separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments that do not have associated convertible features. The carrying amount of the equity component representing the conversion option was $53.5 million and was determined by deducting the fair value of the liability component from the par value of the 2027 Notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. The debt discount is amortized to interest expense over the term of the 2027 Notes at an effective interest rate of 11.17% over the contractual terms of the 2027 Notes. In accounting for the debt issuance costs of $0.4 million related to the 2027 Notes, the Company allocated the total amount incurred to the liability and equity components of the 2027 Notes based on their relative fair values. Issuance costs attributable to the liability component were $0.3 million and will be amortized to interest expense using the effective interest method over the contractual terms of the 2027 Notes. Issuance costs attributable to the equity component were netted with the equity component in stockholders’ equity. The net carrying amount of the liability component of the 2027 Notes was as follows (in thousands): December 31, 2020 December 31, 2019 Principal amount $ 200,000 $ — Unamortized debt discount (56,080) — Unamortized debt issuance cost (278) — Net carrying amount $ 143,642 $ — The net carrying amount of the equity component of the 2027 Notes was as follows (in thousands): December 31, 2020 December 31, 2019 Debt discount related to the value of conversion option $ 53,635 $ — Debt issuance cost (109) — Net carrying amount $ 53,526 $ — The following table sets forth the interest expense recognized related to the 2027 Notes (in thousands): Years Ended December 31, December 31, 2020 December 31, 2019 December 31, 2018 Contractual interest expense $ 6,139 $ — $ — Amortization of debt discount 3,555 — — Amortization of debt issuance cost 17 — — Total interest expense related to the 2027 Notes $ 9,711 $ — $ — |
License and Asset Acquisitions
License and Asset Acquisitions | 12 Months Ended |
Dec. 31, 2020 | |
Business Combinations [Abstract] | |
License and Asset Acquisitions | License and Asset Acquisitions The following purchased assets were accounted for as asset acquisitions as substantially all of the fair value of the assets acquired were concentrated in a group of similar assets and/or the acquired assets were not capable of producing outputs due to the lack of employees and early stage of development. Because the assets had not yet received regulatory approval, the fair value attributable to these assets was recorded as in process research and development (“IPR&D”) expenses in the Company’s consolidated statement of operations for the years ended December 31, 2020, 2019, and 2018. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is resolved. License from Pulmokine, Inc. (Seralutinib) On October 2, 2017, the Company, entered into a license agreement with Pulmokine, Inc. under which it was granted an exclusive worldwide license and sublicense to certain intellectual property rights owned or controlled by Pulmokine to develop and commercialize seralutinib and certain backup compounds for the treatment, prevention and diagnosis of any and all disease or conditions. The Company also has the right to sublicense its rights under the license agreement, subject to certain conditions. The assets acquired are in the early stages of the FDA approval process, and the Company intends to further develop the assets acquired through potential FDA approval as evidenced by the milestone arrangement in the contract. The development activities cannot be performed without significant cost and effort by the Company. The agreement will remain in effect from the effective date, unless terminated earlier, until, on a licensed product-by-licensed product and country-by-country basis, the later of ten years from the date of first commercial sale or when there is no longer a valid patent claim covering such licensed product or specified regulatory exclusivity for the licensed product in such country. The Company is obligated to make future development and regulatory milestone payments of up to $58.0 million, commercial milestone payments of up to $45.0 million, and sales milestone payments of up to $190.0 million. The Company is also obligated to pay tiered royalties on sales for each licensed product, at percentages ranging from the mid-single digits to the high single-digits. The Company made an upfront payment of $5.5 million in October 2017. In December 2020, the Company accrued a milestone payment of $5.0 million in connection with the initiation of the first Phase 2 clinical trial of seralutinib. AA Biopharma Inc. Acquisition (GB001) On January 4, 2018, the Company acquired AA Biopharma Inc. pursuant to a merger agreement, and with the acquisition acquired the rights to GB001 and certain backup compounds. In connection with the merger agreement, the Company issued an aggregate of 20,000,000 shares of Series Seed convertible preferred stock and 1,101,278 shares of common stock to the AA Biopharma shareholders. The Company recorded IPR&D of $19.3 million in connection with the acquisition of AA Biopharma. License from Aerpio Pharmaceuticals, Inc. (GB004) On June 24, 2018, the Company entered into a license agreement with Aerpio Pharmaceuticals, Inc. (“Aerpio”) under which the Company was granted an exclusive worldwide license and sublicense to certain intellectual property rights owned or controlled by Aerpio to develop and commercialize GB004, and certain other related compounds for all applications. The Company made an upfront payment of $20.0 million in June 2018, which represented the purchase consideration for an asset acquisition. On May 11, 2020, the Company entered into an amendment to the license agreement with Aerpio pursuant to which the Company made an upfront payment of $15.0 million to Aerpio for a reduction in future milestone payments and royalties. Under the amended license agreement, the Company is obligated to make future approval milestone payments of up to $40.0 million and a sales milestone payment of $50.0 million. The Company also has the right to sublicense its rights under the license agreement, subject to certain conditions. The Company is also obligated to pay tiered royalties on sales for each licensed product, at percentages ranging from low- to mid-single digits, subject to certain customary reductions. Aerpio retains its twenty percent (20.00%) participation right on a disposition of GB004. As of December 31, 2020, no milestones had been accrued as the underlying contingencies had not yet been resolved. Adhaere Pharmaceuticals, Inc. Acquisition (GB1275) On September 21, 2018, the Company acquired Adhaere Pharmaceuticals, Inc. pursuant to a merger agreement for an upfront payment of $7.5 million in cash, and with the acquisition acquired the rights to GB1275 and certain backup compounds. The Company is obligated to make future regulatory, development and sales milestone payments of up to $62.0 million and pay tiered royalties on worldwide net sales, at percentages ranging from low to mid-single digits, subject to customary reductions. The Company recorded IPR&D of $7.5 million in connection with the acquisition of Adhaere. In May 2019, the Company made a milestone payment of $1.0 million in connection with the filing of the Investigational New Drug application for the GB1275 program. As of December 31, 2020, no other milestones had been accrued as the underlying contingencies had not yet been resolved. The Company recorded the following IPR&D expense on the consolidated statements of operations (in thousands): Years Ended December 31, 2020 2019 2018 Seralutinib $ 5,000 $ — $ — GB004 15,000 — 20,000 GB1275 — 1,000 7,501 GB001 — — 19,148 Other preclinical programs 3,380 2,600 3,010 Total in process research and development $ 23,380 $ 3,600 $ 49,659 |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The amount of net loss before taxes for the years ended December 31, 2020, 2019, and 2018 is as follows: December 31, 2020 2019 2018 (in thousands) U.S. loss before taxes $ 186,888 $ 138,342 $ 116,920 Foreign loss before taxes 56,472 41,965 30,049 Loss before income taxes $ 243,360 $ 180,307 $ 146,969 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities at December 31, 2020, 2019 and 2018 are shown below. The Company has established a valuation allowance against net deferred tax assets due to the uncertainty that such assets will be realized. The Company periodically evaluates the recoverability of the deferred assets. At such time as it is determined that it is more likely than not that the deferred tax asset will be realized, the valuation allowance will be reduced. The change in the valuation allowance for the year ended December 31, 2020 was an increase of $38.9 million. December 31, 2020 2019 2018 (in thousands) Deferred tax assets: Net operating losses $ 77,946 $ 43,626 $ 14,442 Tax credits, net 17,372 9,196 1,131 Amortization 10,939 6,597 6,267 Stock-based compensation 4,448 1,388 — Lease liability 2,383 2,329 — Accrued compensation 2,137 1,476 834 Other 16 383 154 Total gross deferred tax assets 115,241 64,995 22,828 Deferred tax liabilities: Convertible senior notes (10,592) — — Right of use asset (2,215) (2,164) — Property, plant and equipment (776) (57) (16) Stock-based compensation — — (1,057) Total gross deferred tax liabilities (13,583) (2,221) (1,073) Valuation allowance (101,658) (62,774) (21,755) Net deferred tax asset $ — $ — $ — At December 31, 2020, the Company has federal and California NOL carryforwards of approximately $310.7 million and $1.1 million, respectively. The federal NOL carryforwards generated prior to January 1, 2018 begin to expire in 2034. The federal NOL generated after 2017 of $307.7 million can be carried forward indefinitely but may only be used to offset up to 80% of the Company's taxable income in taxable years beginning after December 31, 2020. The California NOL carryforwards begin to expire in 2036. At December 31, 2020, the Company has foreign NOL carryforwards of approximately $101.1 million that can be carried forward indefinitely. At December 31, 2020, the Company also has orphan drug credit and federal research tax credit carryforwards of approximately $17.9 million and California research tax credits of $5.4 million. The federal research tax credit carryforwards begin to expire in 2038 and the California research tax credit carryforward does not expire and can be carried forward indefinitely until utilized. A reconciliation of the federal statutory income tax rate to the Company’s effective income tax rate is as follows: December 31, 2020 2019 2018 Federal statutory income tax rate 21.00 % 21.00 % 21.00 % State income taxes, net of federal benefit — % — % — % Change in valuation allowance (19.50 %) (22.12 %) (13.17 %) Research and experimentation credits 2.76 % 3.81 % 0.77 % Foreign rate differential (1.64 %) (1.84 %) (1.74 %) Stock-based compensation (1.81 %) — % (2.6 %) In process research and development — % — % (3.92 %) Other (0.80 %) (0.85 %) (0.34 %) Provision for income taxes — % — % — % The NOL carryforward may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986 (the “Code”), and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax respectively. In general, an ownership change as defined by Section 382 and 383, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. In connection with the Company’s IPO in February 2019, the Company experienced an ownership change for the purposes of Section 382 and 383 of the Code. The ownership change did not result in the forfeiture of any NOLs or credits generated prior to this date. Consequently, the Company’s federal and state NOLs and tax credits generated through February 2019 will be subject to annual limitations. If a change in ownership occurs in the future, the NOL and tax credits carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company’s effective tax rate. The Company files income tax returns in the United States, California, Ireland, and Luxembourg. Due to the Company’s unutilized NOLs and credits, the Company is subject to the income tax examination by authorities since inception. The Company’s policy is to recognize interest expense and penalties related to income tax matters as tax expense. As of December 31, 2020, 2019, or 2018, there were no significant accruals for interest related to unrecognized tax benefits or tax penalties. On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (“Tax Act”) was signed into law making significant changes to the Internal Revenue Code, including, but are not limited to (a) reducing the federal corporate income tax rate from 35% to 21%, effective January 1, 2018; (b) eliminating the federal corporate alternative minimum tax (“AMT”) and changing how existing AMT credits can be realized; and (c) eliminating several business deductions and credits, including deductions for certain executive compensation in excess of $1 million. As a result of the rate reduction, the Company reduced the deferred tax asset balance as of December 31, 2018 by $0.8 million. Due to the Company's full valuation allowance position, there was no net impact on the Company’s income tax provision at December 31, 2018 as the reduction in the deferred tax asset balance was fully offset by a corresponding decrease in the valuation allowance. A reconciliation of the beginning and ending amount of unrecognized tax benefits for 2020, 2019, and 2018, excluding interest and penalties, is as follows: December 31, 2020 2019 2018 (in thousands) Balance at beginning of the year $ 2,754 $ 408 $ — Increase related to current year positions 2,306 2,346 408 Balance at the end of the year $ 5,060 $ 2,754 $ 408 Included in the balance of unrecognized tax benefits at December 31, 2020 is $5.1 million that, if recognized, would not impact the Company’s income tax benefit or effective tax rate as long as our deferred tax asset remains subject to a |
Stockholders' Equity (Deficit)
Stockholders' Equity (Deficit) | 12 Months Ended |
Dec. 31, 2020 | |
Equity [Abstract] | |
Stockholders' Equity | Stockholders’ Equity In connection with the Company’s IPO, the outstanding shares of the Company’s Series Seed, Series A, and Series B convertible preferred stock automatically converted into 30,493,460 shares of common stock. Each share of common stock is entitled to one vote. Common stock owners are entitled to dividends when funds are legally available and declared by the Board. Shelf Registration Statement and Stock Offering On April 10, 2020, the Company filed a universal shelf registration statement on Form S-3, covering the offering from time to time of common stock, preferred stock, debt securities, warrants and units, which registration statement became automatically effective on April 10, 2020 (the “Shelf Registration Statement”). On May 21, 2020, the Company completed a public offering of 9,433,963 shares of its common stock at a public offering price of $13.25 per share. The net proceeds from the offering, after deducting underwriting discounts and commissions and other offering costs, were approximately $117.1 million. The shares sold in the offering were registered pursuant to the Company’s Shelf Registration Statement. Shares of Common Stock Subject to Repurchase On December 3, 2015, the Company issued 9,160,888 shares of common stock as founder shares for services rendered to the Company, valued at $0.0001 par value per share, for a total of approximately $4,100 (the “founder shares”). On January 4, 2018, incremental vesting conditions were placed on the previously issued founder shares. Fifty percent of the previously issued founder shares vested on January 4, 2018, and the remaining founder shares are subject to vesting restrictions over a period of five years. These shares are subject to repurchase by the Company upon a founder's termination of employment or service to the Company. Pursuant to the employment agreements with the Company’s founders executed January 4, 2018, the Company provided for certain potential additional issuances of common stock (the “anti-dilution shares”) to each of the founders to ensure the total number of shares of common stock held by them and their affiliates (inclusive of any shares subject to equity awards granted by the Company and the Founders’ Equity) would represent 15% of the Company’s fully-diluted capitalization until such time as the Company raised $300.0 million in equity capital, including the capital raised in the Series A financing. In furtherance of this obligation, on May 21, 2018, the Company issued 251,547 shares of common stock to the founders for services rendered to the Company, valued at $2.61 per share with an additional 251,547 shares of restricted stock subject to the same vesting restrictions and vesting period as the founder shares. In addition, on September 6, 2018, the Company issued 1,795,023 shares of common stock to the founders for services rendered to the Company, valued at $9.63 per share, with an additional 1,795,023 shares of restricted stock subject to the same vesting restrictions and vesting period as the founder shares. In November 2017, in connection with the issuance of the Series A convertible preferred stock, certain employees entered into stock restriction agreements, whereby 1,305,421 shares are subject to repurchase by the Company upon the stockholder’s termination of employment or service to the Company. For the year ended December 31, 2020, 441,801 shares were forfeited due to termination of employment. Any shares subject to repurchase by the Company are not deemed, for accounting purposes, to be outstanding until those shares vest. As such, the Company recognizes the measurement date fair value of the restricted stock over the vesting period as compensation expense. As of December 31, 2020, 2019 and 2018, 1,649,348 shares, 4,648,526 shares and 7,482,032 shares of common stock, respectively, were subject to repurchase by the Company. The unvested stock liability related to these awards is immaterial to all periods presented. |
Equity Incentive Plans
Equity Incentive Plans | 12 Months Ended |
Dec. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Equity Incentive Plans | Equity Incentive Plans 2019 Equity Incentive Plan In January 2019, the Company’s board of directors and stockholders approved and adopted the 2019 Incentive Award Plan (the “2019 Plan”). The 2019 Plan became effective on February 6, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. Under the 2019 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock or cash-based awards to individuals who are then employees, officers, directors or consultants of the Company, and employees and consultants of the Company’s subsidiaries. A total of 5,750,000 shares of common stock were approved to be initially reserved for issuance under the 2019 Plan. The number of shares that remained available for issuance under the 2017 Plan (as defined below) as of the effective date of the 2019 Plan were, and shares subject to outstanding awards under the 2017 Plan as of the effective date of the 2019 Plan that are subsequently canceled, forfeited or repurchased by the Company will be added to the shares reserved under the 2019 Plan. In addition, the number of shares of common stock available for issuance under the 2019 Plan will be automatically increased on the first day of each calendar year during the ten 2019 Employee Stock Purchase Plan In January 2019, the Company’s board of directors and stockholders approved and adopted the ESPP. The ESPP became effective as of February 6, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. A total of 700,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will be automatically increased on the first day of each calendar year during the first ten-years of the term of the ESPP, beginning with January 1, 2020 and ending with January 1, 2029, by an amount equal to 1% of the outstanding number of shares of the Company’s common stock on December 31 of the preceding calendar year or such lesser amount as determined by the Company’s board of directors. During the year ended December 31, 2020, 113,286 shares were issued pursuant to the ESPP. As of December 31, 2020, an aggregate of 1,249,554 shares of common stock were available for issuance under the ESPP. 2017 Equity Incentive Plan The Company’s 2017 Equity Incentive Plan (the “2017 Plan”) permitted the granting of incentive stock options, non-statutory stock options, restricted stock, restricted stock units and other stock-based awards. Subsequent to the adoption of the 2019 Plan, no additional equity awards can be made under the 2017 Plan. As of December 31, 2020, 3,941,562 shares of common stock were subject to outstanding options under the 2017 Plan, and 268,719 shares of restricted stock awards granted under the 2017 plan were unvested. Fair Value of Stock Option Awards The fair value of each employee and non-employee stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company estimates its expected volatility based on the historical volatility of a publicly traded set of peer companies. Due to the lack of historical exercise history, the expected term of the Company’s stock options for employees has been determined utilizing the “simplified” method for awards. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The following assumptions were used to estimate the fair value of stock option awards granted to employees under the Company’s equity incentive plans and the shares purchasable under the ESPP during the periods presented: Year Ended December 31, 2020 2019 2018 Employee Stock Options Expected term (in years) 4.6 - 6.1 4.6 - 6.1 5.3 - 6.1 Risk-free interest rate 0.22% - 1.67% 1.38% - 2.58% 2.65% - 2.96% Volatility 84.38% - 87.23% 70.25% - 86.92% 69.13% - 77.62% Dividend yield — — — Employee Stock Purchase Plan Expected term (in years) 0.49 - 2.00 0.49 - 1.99 N/A Risk-free interest rate 0.12% -0.95% 1.46% - 1.87% N/A Volatility 85.50% - 99.13% 72.08% - 78.70% N/A Dividend yield — — N/A Stock Options The following table summarizes stock option activity for the years ended December 31, 2020, 2019 and 2018: Shares Subject to Weighted- Aggregate Shares Weighted- (in thousands) Outstanding as of December 31, 2017 — $ — 0.0 $ — Options granted 5,143,551 $ 7.49 Options exercised — $ — Options forfeited/cancelled (36,222) $ 4.85 Outstanding as of December 31, 2018 5,107,329 $ 7.51 9.7 $ 16,343 Options granted 4,194,624 $ 20.11 Options exercised (419,593) $ 4.87 Options forfeited/cancelled (344,300) $ 11.64 Outstanding as of December 31, 2019 8,538,060 $ 13.67 9.0 $ 35,385 Options granted 2,712,372 $ 13.78 Options exercised (134,803) $ 3.96 Options forfeited/cancelled (1,714,547) $ 15.99 Outstanding as of December 31, 2020 9,401,082 $ 13.42 8.1 $ 10,182 Options vested and exercisable as of December 31, 2020 3,749,170 $ 12.66 7.5 $ 6,293 The weighted-average grant date fair value per share for the stock options granted during the year ended December 31, 2020, 2019 and 2018 was $9.82, $13.17 and $4.87, respectively. The aggregate fair value of stock options that vested during the years ended December 31, 2020, 2019 and 2018 was $29.9 million, $7.2 million and $0.1 million, respectively. The aggregate intrinsic value in the above table is calculated as the difference between fair value of the Company’s common stock price and the exercise price of the stock options. The aggregate intrinsic value of stock options exercised during the year ended December 31, 2020 and 2019 was $1.1 million and $6.9 million, respectively. There were no stock options exercised during the year ended December 31, 2018. At December 31, 2020, the total unrecognized compensation related to unvested stock option awards granted was $48.1 million, which the Company expects to recognize over a weighted-average period of approximately 2.4 years. Restricted Stock The summary of the Company’s restricted stock activity during the years ended December 31, 2020, 2019 and 2018 is as follows: Number of Weighted- Nonvested at December 31, 2017 1,305,421 $ 0.09 Granted 8,673,584 5.53 Vested (2,369,696) 7.58 Forfeited (127,277) 0.09 Nonvested at December 31, 2018 7,482,032 $ 4.01 Granted — — Vested (2,833,506) 4.05 Forfeited — — Nonvested at December 31, 2019 4,648,526 $ 3.98 Granted 2,003,900 10.96 Vested (2,557,377) 4.00 Forfeited (764,228) 8.30 Nonvested at December 31, 2020 3,330,821 $ 7.16 At December 31, 2020, the total unrecognized compensation related to unvested restricted stock awards granted was $18.8 million, which the Company expects to recognize over a weighted-average period of approximately 1.9 years. Stock-Based Compensation Expense Stock-based compensation expense has been reported in the Company’s consolidated statements of operations as follows (in thousands): Year Ended December 31, 2020 2019 2018 Research and development $ 18,997 $ 10,227 $ 679 General and administrative 19,751 10,592 30,268 Total stock-based compensation $ 38,748 $ 20,819 $ 30,947 In connection with the departure of the Company's former President and Chief Executive Officer in November 2020, the Company recognized $5.5 million of incremental stock-based compensation expense during the year ended December 31, 2020, due to a modification of the executive's existing restricted stock award, which included 18 months of accelerated vesting of the executive's outstanding restricted stock in accordance with the terms of the executive's transition agreement. As of December 31, 2020, total unrecognized compensation expense related to the ESPP was $1.4 million, which the Company expects to recognize over a weighted-average period of approximately 1 year. |
Property and Equipment, Net
Property and Equipment, Net | 12 Months Ended |
Dec. 31, 2020 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment, Net | Property and Equipment, Net The Company’s property and equipment, net consisted of the following (in thousands): Estimated December 31, December 31, Office equipment 3-7 $ 1,153 $ 1,097 Computer equipment 5 123 124 Software 3 116 87 Lab equipment 2-5 4,210 3,054 Leasehold improvements 6-7 2,540 2,229 Construction in process N/A 15 48 Total property and equipment 8,157 6,639 Less: accumulated depreciation 2,623 1,214 Property and equipment, net $ 5,534 $ 5,425 Depreciation expense for the years ended December 31, 2020, 2019 and 2018 was approximately $1.4 million, $0.9 million and $0.3 million, respectively, and was recorded in general and administrative expense in the consolidated statements of operations. |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Leases The Company subleases certain office and laboratory space under a non-cancelable operating lease expiring in January 2025 for the initial leased space and December 2022 for expansion space leased pursuant to an amendment to the lease agreement entered into in August 2018. The sublease agreement included options to extend for the entire premises through October 2028. The options to extend must be exercised prior to the termination of the original lease agreement. The period covered by the options was not included in the non-cancellable lease term as it was not determined to be reasonably certain to be executed. The lease agreement also includes a one-time termination option for the expansion space only whereby the Company can terminate the lease with advance written notice. The termination option was not determined to be reasonably certain to be executed. The lease is subject to charges for common area maintenance and other costs, and base rent is subject to an annual 3% increase each subsequent year. Costs determined to be variable and not based on an index or rate were not included in the measurement of the operating lease liabilities. In November 2019, the Company entered into an additional non-cancelable lease agreement for certain office and laboratory space (the “permanent space”) in San Diego, California, commencing on May 1, 2020 and expiring on December 31, 2021. The lease agreement includes a lease for temporary space commencing on January 1, 2020 and expiring on the commencement date of the lease of the permanent space. The monthly base rent for the permanent and temporary space is $63,425 and $28,745, respectively. The lease agreement included an option to extend the term of the permanent space for twelve months. The option to extend must be exercised nine months prior to the termination of the original lease agreement. The period covered by the option was not included in the non-cancellable lease term as it was not determined to be reasonably certain to be executed. The lease is subject to charges for common area maintenance and other costs, and base rent is subject to an annual 3% increase each subsequent year. In June 2020, the Company entered into a sublease agreement for the permanent space with a third party. The sublease commenced on July 1, 2020 and expires on December 31, 2021. The sublessee pays the monthly base rent of $63,425, subject to an annual 3% increase, and is obligated to pay for common area maintenance and other costs. The sublessee received a 6 months base rent abatement. The Company determined that there was no impairment on the original right-of-use asset and will continue to account for the permanent space as it did before the commencement of the sublease. The Company recognized $0.2 million in sublease income for the year ended December 31, 2020. On July 29, 2020, the Company entered into a lease assignment agreement, whereby it became the assignee to a lease for certain office and laboratory space in Ann Arbor, Michigan. The lease term expires on December 31, 2026 and the Company has the option to extend the term of the lease by up to five years. The period covered by the option was not included in the non-cancellable lease term as it was not determined to be reasonably certain to be executed. The monthly base rent for the space is $28,495. The lease is subject to charges for common area maintenance and other costs, and base rent is subject to an annual 2.5% increase on January 1 of each year. Monthly rent expense is recognized on a straight-line basis over the term of the leases. The operating leases are included in the balance sheet at the present value of the lease payments at a weighted average discount rate of 7% using the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as the leases do not provide an implicit rate. The weighted average remaining lease term was 3.4 years. Lease costs were comprised of the following (in thousands): Year ended December 31, 2020 Operating lease cost $ 3,615 Short-term lease cost 78 Total lease cost $ 3,693 Cash paid for amounts included in the measurement of operating lease liabilities for the years ended December 31, 2020 and 2019 was $3.6 million and $3.0 million , respectively. Gross future minimum annual rental commitments as of December 31, 2020, were as follows (in thousands): Undiscounted Rent Year ending December 31, 2021 $ 4,273 2022 3,579 2023 2,063 2024 2,123 2025 387 397 Total undiscounted rent payments $ 12,822 Present value discount (1,476) Present value $ 11,346 Current portion of operating lease liabilities (included as a component of accrued expenses and other current liabilities) 3,633 Noncurrent operating lease liabilities 7,713 Total operating lease liability $ 11,346 For the years ended December 31, 2020, 2019 and 2018, the Company recorded approximately $4.0 million, $3.1 million and $1.5 million, respectively, in rent expense. Litigation Kuhne vs. Gossamer Bio, Inc., et. al. On April 3, 2020, Scott Kuhne, individually and on behalf of all others similarly situated, filed a putative class action lawsuit against the Company, certain of its executive officers and directors, and the underwriters of its IPO in the United States District Court for the Southern District of California (Case No. 3:20-cv-00649-DMS-DEB). The first amended complaint was filed on August 31, 2020, and the second amended complaint was filed on November 20, 2020. The second amended complaint was filed on behalf of all investors who purchased the Company's securities pursuant to or traceable to the Company's February 8, 2019 IPO. The second amended complaint alleges that the Company, certain of its executive officers and directors, and the underwriters of its IPO made false and/or misleading statements and failed to disclose material adverse facts about its business, operations and prospects in violation of Sections 11 and 15 of the Securities Act of 1933, as amended. The plaintiff seeks damages, interest, costs, attorneys’ fees, and other unspecified equitable relief. The Company moved to dismiss the second amended complaint on January 19, 2021, and Plaintiff filed an opposition to the motion on February 18, 2021. The Company’s deadline to file a reply in support of the motion to dismiss is March 22, 2021. The Company intends to vigorously defend this matter. Given the uncertainty of litigation, the preliminary stage of the case, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may result from this action. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Certain prior period amounts have been reclassified to conform to the current period presentation. |
Use of Estimates | Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s consolidated financial statements relate to the allocation of the 2027 Notes into liability and equity components and accrued research and development expenses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates. |
Segments | Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which approximate their fair value. |
Marketable Securities | Marketable Securities The Company considers securities with original maturities of greater than 90 days to be marketable securities. The Company has the ability, if necessary, to liquidate any of its cash equivalents and marketable securities to meet its liquidity needs in the next 12 months. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as current assets on the accompanying condensed consolidated balance sheets. The Company’s marketable securities consist of U.S. Treasury and agency securities, commercial paper, and corporate debt securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are due to credit-related factors. The Company records an allowance for credit losses when unrealized losses are due to credit-related factors. Realized gains and losses are calculated using the specific identification method and recorded as interest income or expense. The Company does not generally intend to sell the investments and it is not more likely than not that it will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The Company has determined that there were no material declines in fair values of its investments due to credit-related factors as of December 31, 2020. |
Restricted Cash | Restricted Cash Restricted cash as of December 31, 2020, and 2019 represents cash held as collateral for the Company's facility leases. Restricted cash as of December 31, 2018 served as collateral for the Company’s corporate credit card program. |
Concentrations of Credit Risk and Off-Balance Sheet Risk | Concentrations of Credit Risk and Off-Balance Sheet Risk Cash, cash equivalents and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in U.S. Treasury and agency securities and commercial paper with maturities less than three months and in money market funds that invest in U.S. Treasury and agency securities. The Company’s available for sale securities are also invested in U.S. Treasury and agency securities. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents and available for sale securities. |
Property and Equipment, Net | Property and Equipment, Net Property and equipment, net, which consists mainly of office equipment and leasehold improvements, are carried at cost less accumulated depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally three to seven years, using the straight-line method. |
Convertible Senior Notes | Convertible Senior Notes In accounting for the issuance of the 2027 Notes, the Company separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments that do not have associated convertible features. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2027 Notes. The equity component is not remeasured as long as it continues to meet the condition for equity classification. The excess of the principal amount of the liability component over its carrying amount (“debt discount”) is amortized to interest expense over the term of the 2027 Notes. The Company allocated the issuance costs incurred to the liability and equity components of the 2027 Notes based on their relative fair values. Issuance costs attributable to the liability component were recorded as a reduction to the liability portion of the 2027 Notes and are being amortized to interest expense over the term of the 2027 Notes. Issuance costs attributable to the equity component, representing the conversion option, were netted with the equity component in stockholders' equity. |
Leases | Leases In accordance with Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), as adopted on January 1, 2019, the Company determines if an arrangement is a lease at inception. Operating leases are included in the balance sheet as right-of-use assets and operating lease liabilities at the present value of the lease payments calculated using the Company’s incremental borrowing rate, unless the implicit rate is readily available. The Company applied the short-term lease recognition exemption for leases with terms at inception not greater than 12 months and elected to not separate lease and non-lease components for its long-term leases. The Company records rent expense on a straight-line basis over the term of the lease. |
Research and Development | Research and Development All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services) and in process research and development expenses. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractor’s bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial. Upfront costs, such as costs associated with setting up clinical trial sites for participation in the trials, are expensed immediately once incurred as research and development expenses. |
Patent Costs | Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses. |
Income Taxes | Income Taxes Income taxes are recorded in accordance with Financial Accounting Standards Board (“FASB”) Standards Codification (“ASC”) No. 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. Deferred tax assets and liabilities reflect the future tax consequences of the differences between the financial reporting and tax bases of assets and liabilities using current enacted tax rates. Valuation allowances are recorded when the realizability of such deferred tax assets does not meet a more-likely-than-not threshold. For tax benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company is subject to taxation in the United States and California, Ireland and Luxembourg. As of December 31, 2020, the Company’s tax years since inception are subject to examination by taxing authorities due to the Company’s unutilized net operating losses ("NOLs") and tax credits. |
Stock-Based Compensation | Stock-Based Compensation The Company expenses stock-based compensation to employees and non-employees over the requisite service period based on the estimated grant-date fair value of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the requisite service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants and shares purchasable under the Company's 2019 Employee Stock Purchase Plan ("ESPP") using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company estimates the fair value of restricted stock units based on the closing price of the Company's common stock on the date of grant. The Company accounts for forfeitures as they occur. All share-based compensation costs are recorded in the statements of operations based upon the underlying employees or non-employee’s roles within the Company. |
Foreign Currency | Foreign Currency Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where that local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense accounts are translated at average exchange rates during the year which approximate the rates in effect at the transaction dates. The resulting translation adjustments are recorded in accumulated other comprehensive income (loss). Foreign exchange transaction gains and losses are included in other income (expense) in the Company’s consolidated statement of operations and comprehensive loss. |
Recent Accounting Pronouncements To Be Adopted and Recently Adopted Accounting Pronouncements | Recent Accounting Pronouncements—To Be Adopted In August 2020, the FASB issued ASU 2020-06, Debt: Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40) (“ASU 2020-06”), which simplifies the accounting for convertible instruments and contracts in an entity's own equity. This guidance is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those years, with early adoption permitted only as of annual reporting periods beginning after December 15, 2020. The Company is currently assessing the impact this standard will have on its consolidated financial statements or related financial statement disclosures. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which changes the impairment model for most financial assets and certain other instruments. For trade receivables and other instruments, entities will be required to use a new forward-looking expected loss model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. This guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those years, with early adoption permitted only as of annual reporting periods beginning after December 15, 2018. The Company adopted ASU 2016-13 as of January 1, 2020. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements or related financial statement disclosures. |
Net Loss Per Share | Net Loss Per Share Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The Company uses the if-converted method for assumed conversion of the 2027 Notes to compute the weighted average shares of common stock outstanding for diluted net loss per share. Diluted net loss per share excludes the potential impact of the Company's Series Seed convertible preferred stock, Series A convertible preferred stock, and Series B convertible preferred stock, common stock options and unvested shares of restricted stock and the potential shares issuable upon conversion of the 2027 Notes because their effect would be anti-dilutive due to the Company’s net loss. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the same. The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive: December 31, 2020 2019 2018 Shares issuable upon conversion of Series Seed convertible preferred stock — — 4,444,444 Shares issuable upon conversion of Series A convertible preferred stock — — 10,158,710 Shares issuable upon conversion of Series B convertible preferred stock — — 15,890,306 2027 Notes 12,321,900 — — Shares issuable upon exercise of stock options 9,401,082 8,538,060 5,107,329 Non-vested shares under restricted stock grants 3,330,821 4,648,526 7,482,032 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share | The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive: December 31, 2020 2019 2018 Shares issuable upon conversion of Series Seed convertible preferred stock — — 4,444,444 Shares issuable upon conversion of Series A convertible preferred stock — — 10,158,710 Shares issuable upon conversion of Series B convertible preferred stock — — 15,890,306 2027 Notes 12,321,900 — — Shares issuable upon exercise of stock options 9,401,082 8,538,060 5,107,329 Non-vested shares under restricted stock grants 3,330,821 4,648,526 7,482,032 |
Accrued Expenses and Other Cu_2
Accrued Expenses and Other Current Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses and Other Current Liabilities | Accrued expenses and other current liabilities consisted of the following (in thousands): Years Ended December 31, 2020 2019 Accrued compensation $ 12,194 $ 9,282 Operating lease liabilities, current 3,633 2,354 Accrued consulting fees 1,919 1,337 Accrued interest, current 1,094 — Accrued other 742 1,126 Accrued legal fees 619 837 Accrued accounting fees 285 173 Accrued in process research and development 225 1,600 Total accrued expenses $ 20,711 $ 16,709 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Assets Measured at Fair Value on Recurring Basis | The following table presents the hierarchy for assets measured at fair value on a recurring basis as of December 31, 2020 and December 31, 2019 (in thousands): Fair Value Measurements at End of Period Using: Total Quoted Market Significant Significant As of December 31, 2020 Money market funds $ 411,104 $ 411,104 $ — $ — U.S. Treasury and agency securities 18,280 18,280 — — Corporate debt securities 26,573 — 26,573 — As of December 31, 2019 Money market funds $ 82,125 $ 82,125 $ — $ — U.S. Treasury and agency securities 91,717 91,717 — — Commercial paper 37,411 — 37,411 — Corporate debt securities 156,277 — 156,277 — |
Schedule of Available for Sale Investments by Security Type | The aggregate market value, cost basis, and gross unrealized gains and losses of available-for-sale investments by security type, classified in marketable securities and long-term investments as of December 31, 2020 are as follows (in thousands): Amortized Gross Gross Total Marketable securities Corporate debt securities $ 26,396 $ 177 $ — $ 26,573 Total marketable securities $ 26,396 $ 177 $ — $ 26,573 |
Schedule of Contractual Maturities of Available-for-sale Debt Securities | Contractual maturities of available-for-sale debt securities, as of December 31, 2020, were as follows (in thousands): Estimated Due within one year $ 26,573 One to two years — Total $ 26,573 |
Indebtedness (Tables)
Indebtedness (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Debt Disclosure [Abstract] | |
Schedule of Long-Term Debt | Long-term debt as of December 31, 2020 consisted of the following (in thousands): December 31, 2020 Term loan $ 30,000 Debt discount and issuance costs (1,256) Long-term debt $ 28,744 The net carrying amount of the liability component of the 2027 Notes was as follows (in thousands): December 31, 2020 December 31, 2019 Principal amount $ 200,000 $ — Unamortized debt discount (56,080) — Unamortized debt issuance cost (278) — Net carrying amount $ 143,642 $ — The net carrying amount of the equity component of the 2027 Notes was as follows (in thousands): December 31, 2020 December 31, 2019 Debt discount related to the value of conversion option $ 53,635 $ — Debt issuance cost (109) — Net carrying amount $ 53,526 $ — The following table sets forth the interest expense recognized related to the 2027 Notes (in thousands): Years Ended December 31, December 31, 2020 December 31, 2019 December 31, 2018 Contractual interest expense $ 6,139 $ — $ — Amortization of debt discount 3,555 — — Amortization of debt issuance cost 17 — — Total interest expense related to the 2027 Notes $ 9,711 $ — $ — |
Schedule of Future Minimum Principal Payments | The scheduled future minimum principal payments are as follows (in thousands): December 31, 2020 2021 — 2022 5,806 2023 11,613 2024 11,613 2025 968 Total $ 30,000 |
License and Asset Acquisitions
License and Asset Acquisitions (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Business Combinations [Abstract] | |
Schedule of IPR&D Expense | The Company recorded the following IPR&D expense on the consolidated statements of operations (in thousands): Years Ended December 31, 2020 2019 2018 Seralutinib $ 5,000 $ — $ — GB004 15,000 — 20,000 GB1275 — 1,000 7,501 GB001 — — 19,148 Other preclinical programs 3,380 2,600 3,010 Total in process research and development $ 23,380 $ 3,600 $ 49,659 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
Schedule of Amount of Net Loss Before Taxes | The amount of net loss before taxes for the years ended December 31, 2020, 2019, and 2018 is as follows: December 31, 2020 2019 2018 (in thousands) U.S. loss before taxes $ 186,888 $ 138,342 $ 116,920 Foreign loss before taxes 56,472 41,965 30,049 Loss before income taxes $ 243,360 $ 180,307 $ 146,969 |
Schedule of Deferred Tax Assets and Liabilities | December 31, 2020 2019 2018 (in thousands) Deferred tax assets: Net operating losses $ 77,946 $ 43,626 $ 14,442 Tax credits, net 17,372 9,196 1,131 Amortization 10,939 6,597 6,267 Stock-based compensation 4,448 1,388 — Lease liability 2,383 2,329 — Accrued compensation 2,137 1,476 834 Other 16 383 154 Total gross deferred tax assets 115,241 64,995 22,828 Deferred tax liabilities: Convertible senior notes (10,592) — — Right of use asset (2,215) (2,164) — Property, plant and equipment (776) (57) (16) Stock-based compensation — — (1,057) Total gross deferred tax liabilities (13,583) (2,221) (1,073) Valuation allowance (101,658) (62,774) (21,755) Net deferred tax asset $ — $ — $ — |
Reconciliation of the Federal Statutory Income Tax Rate to Effective Income Tax Rate | A reconciliation of the federal statutory income tax rate to the Company’s effective income tax rate is as follows: December 31, 2020 2019 2018 Federal statutory income tax rate 21.00 % 21.00 % 21.00 % State income taxes, net of federal benefit — % — % — % Change in valuation allowance (19.50 %) (22.12 %) (13.17 %) Research and experimentation credits 2.76 % 3.81 % 0.77 % Foreign rate differential (1.64 %) (1.84 %) (1.74 %) Stock-based compensation (1.81 %) — % (2.6 %) In process research and development — % — % (3.92 %) Other (0.80 %) (0.85 %) (0.34 %) Provision for income taxes — % — % — % |
Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties | A reconciliation of the beginning and ending amount of unrecognized tax benefits for 2020, 2019, and 2018, excluding interest and penalties, is as follows: December 31, 2020 2019 2018 (in thousands) Balance at beginning of the year $ 2,754 $ 408 $ — Increase related to current year positions 2,306 2,346 408 Balance at the end of the year $ 5,060 $ 2,754 $ 408 |
Equity Incentive Plans (Tables)
Equity Incentive Plans (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Summary of Fair Value of Stock Option Award Granted | The following assumptions were used to estimate the fair value of stock option awards granted to employees under the Company’s equity incentive plans and the shares purchasable under the ESPP during the periods presented: Year Ended December 31, 2020 2019 2018 Employee Stock Options Expected term (in years) 4.6 - 6.1 4.6 - 6.1 5.3 - 6.1 Risk-free interest rate 0.22% - 1.67% 1.38% - 2.58% 2.65% - 2.96% Volatility 84.38% - 87.23% 70.25% - 86.92% 69.13% - 77.62% Dividend yield — — — Employee Stock Purchase Plan Expected term (in years) 0.49 - 2.00 0.49 - 1.99 N/A Risk-free interest rate 0.12% -0.95% 1.46% - 1.87% N/A Volatility 85.50% - 99.13% 72.08% - 78.70% N/A Dividend yield — — N/A |
Summary of Stock Option Activity | The following table summarizes stock option activity for the years ended December 31, 2020, 2019 and 2018: Shares Subject to Weighted- Aggregate Shares Weighted- (in thousands) Outstanding as of December 31, 2017 — $ — 0.0 $ — Options granted 5,143,551 $ 7.49 Options exercised — $ — Options forfeited/cancelled (36,222) $ 4.85 Outstanding as of December 31, 2018 5,107,329 $ 7.51 9.7 $ 16,343 Options granted 4,194,624 $ 20.11 Options exercised (419,593) $ 4.87 Options forfeited/cancelled (344,300) $ 11.64 Outstanding as of December 31, 2019 8,538,060 $ 13.67 9.0 $ 35,385 Options granted 2,712,372 $ 13.78 Options exercised (134,803) $ 3.96 Options forfeited/cancelled (1,714,547) $ 15.99 Outstanding as of December 31, 2020 9,401,082 $ 13.42 8.1 $ 10,182 Options vested and exercisable as of December 31, 2020 3,749,170 $ 12.66 7.5 $ 6,293 |
Summary of Restricted Stock Activity | The summary of the Company’s restricted stock activity during the years ended December 31, 2020, 2019 and 2018 is as follows: Number of Weighted- Nonvested at December 31, 2017 1,305,421 $ 0.09 Granted 8,673,584 5.53 Vested (2,369,696) 7.58 Forfeited (127,277) 0.09 Nonvested at December 31, 2018 7,482,032 $ 4.01 Granted — — Vested (2,833,506) 4.05 Forfeited — — Nonvested at December 31, 2019 4,648,526 $ 3.98 Granted 2,003,900 10.96 Vested (2,557,377) 4.00 Forfeited (764,228) 8.30 Nonvested at December 31, 2020 3,330,821 $ 7.16 |
Stock-Based Compensation Expense Reported in Condensed Consolidated Statements of Operations | Stock-based compensation expense has been reported in the Company’s consolidated statements of operations as follows (in thousands): Year Ended December 31, 2020 2019 2018 Research and development $ 18,997 $ 10,227 $ 679 General and administrative 19,751 10,592 30,268 Total stock-based compensation $ 38,748 $ 20,819 $ 30,947 |
Property and Equipment, Net (Ta
Property and Equipment, Net (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and Equipment, Net | The Company’s property and equipment, net consisted of the following (in thousands): Estimated December 31, December 31, Office equipment 3-7 $ 1,153 $ 1,097 Computer equipment 5 123 124 Software 3 116 87 Lab equipment 2-5 4,210 3,054 Leasehold improvements 6-7 2,540 2,229 Construction in process N/A 15 48 Total property and equipment 8,157 6,639 Less: accumulated depreciation 2,623 1,214 Property and equipment, net $ 5,534 $ 5,425 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Lease Costs | Lease costs were comprised of the following (in thousands): Year ended December 31, 2020 Operating lease cost $ 3,615 Short-term lease cost 78 Total lease cost $ 3,693 |
Schedule of Gross Future Minimum Annual Rental Commitments | Gross future minimum annual rental commitments as of December 31, 2020, were as follows (in thousands): Undiscounted Rent Year ending December 31, 2021 $ 4,273 2022 3,579 2023 2,063 2024 2,123 2025 387 397 Total undiscounted rent payments $ 12,822 Present value discount (1,476) Present value $ 11,346 Current portion of operating lease liabilities (included as a component of accrued expenses and other current liabilities) 3,633 Noncurrent operating lease liabilities 7,713 Total operating lease liability $ 11,346 |
Organization and Basis of Pre_2
Organization and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | May 21, 2020 | Feb. 12, 2019 | Jan. 04, 2018 | Feb. 28, 2019 | Dec. 31, 2020 | Dec. 31, 2019 |
Organization and Basis of Presentation [Line Items] | ||||||
Sale of shares of common stock (in shares) | 9,433,963 | |||||
Offering price (in dollars per share) | $ 13.25 | |||||
Retained earnings (accumulated deficit) | $ (577,530) | $ (334,170) | ||||
Funds raised through Series A and Series B Convertible Preferred Stock, convertible note financings and completed IPO | $ 942,000 | |||||
2027 Notes | ||||||
Organization and Basis of Presentation [Line Items] | ||||||
Interest rate | 5.00% | |||||
AA Biopharma Inc. | ||||||
Organization and Basis of Presentation [Line Items] | ||||||
Cash received in connection with acquisition | $ 12,800 | |||||
Initial Public Offering ("IPO") | ||||||
Organization and Basis of Presentation [Line Items] | ||||||
Sale of shares of common stock (in shares) | 19,837,500 | |||||
Offering price (in dollars per share) | $ 16 | |||||
Net proceeds, after deducting underwriting discounts, commissions, and offering expenses | $ 291,300 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Additional Information (Details) | 12 Months Ended |
Dec. 31, 2020segment | |
Accounting Policies [Abstract] | |
Number of operating segments | 1 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share (Details) - shares | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Shares issuable upon conversion of Series Seed convertible preferred stock | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Potentially dilutive securities not included from calculation of diluted net loss per share (in shares) | 0 | 0 | 4,444,444 |
Shares issuable upon conversion of Series A convertible preferred stock | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Potentially dilutive securities not included from calculation of diluted net loss per share (in shares) | 0 | 0 | 10,158,710 |
Shares issuable upon conversion of Series B convertible preferred stock | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Potentially dilutive securities not included from calculation of diluted net loss per share (in shares) | 0 | 0 | 15,890,306 |
2027 Notes | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Potentially dilutive securities not included from calculation of diluted net loss per share (in shares) | 12,321,900 | 0 | 0 |
Shares issuable upon exercise of stock options | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Potentially dilutive securities not included from calculation of diluted net loss per share (in shares) | 9,401,082 | 8,538,060 | 5,107,329 |
Non-vested shares under restricted stock grants | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||
Potentially dilutive securities not included from calculation of diluted net loss per share (in shares) | 3,330,821 | 4,648,526 | 7,482,032 |
Accrued Expenses and Other Cu_3
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Payables and Accruals [Abstract] | ||
Accrued compensation | $ 12,194 | $ 9,282 |
Operating lease liabilities, current | $ 3,633 | $ 2,354 |
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] | us-gaap:AccruedLiabilitiesCurrent | us-gaap:AccruedLiabilitiesCurrent |
Accrued consulting fees | $ 1,919 | $ 1,337 |
Accrued interest, current | 1,094 | 0 |
Accrued other | 742 | 1,126 |
Accrued legal fees | 619 | 837 |
Accrued accounting fees | 285 | 173 |
Accrued in process research and development | 225 | 1,600 |
Total accrued expenses | $ 20,711 | $ 16,709 |
Fair Value Measurements - Asset
Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details) - Recurring Basis - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | $ 411,104 | $ 82,125 |
U.S. Treasury and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 18,280 | 91,717 |
Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 37,411 | |
Corporate debt securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 26,573 | 156,277 |
Quoted Market Prices for Identical Assets (Level 1) | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 411,104 | 82,125 |
Quoted Market Prices for Identical Assets (Level 1) | U.S. Treasury and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 18,280 | 91,717 |
Quoted Market Prices for Identical Assets (Level 1) | Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 0 | |
Quoted Market Prices for Identical Assets (Level 1) | Corporate debt securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 0 | 0 |
Significant Other Observable Inputs (Level 2) | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 0 | 0 |
Significant Other Observable Inputs (Level 2) | U.S. Treasury and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 0 | 0 |
Significant Other Observable Inputs (Level 2) | Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 37,411 | |
Significant Other Observable Inputs (Level 2) | Corporate debt securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 26,573 | 156,277 |
Significant Unobservable Inputs (Level 3) | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 0 | 0 |
Significant Unobservable Inputs (Level 3) | U.S. Treasury and agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 0 | 0 |
Significant Unobservable Inputs (Level 3) | Commercial paper | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | 0 | |
Significant Unobservable Inputs (Level 3) | Corporate debt securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Assets measured at fair value on recurring basis | $ 0 | $ 0 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions | Dec. 31, 2020 | Dec. 31, 2019 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | $ 18.3 | $ 18.7 |
Significant Other Observable Inputs (Level 2) | 2027 Notes | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt, fair value | 198.5 | |
Prepaid Expenses and Other Current Assets | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Interest receivable | $ 0.2 | $ 1.5 |
Fair Value Measurements - Sched
Fair Value Measurements - Schedule of Available for sale Investments by Security Type (Details) $ in Thousands | Dec. 31, 2020USD ($) |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Amortized Cost | $ 26,396 |
Gross Unrealized Gains | 177 |
Gross Unrealized Losses | 0 |
Total Fair Value | 26,573 |
Corporate debt securities | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Amortized Cost | 26,396 |
Gross Unrealized Gains | 177 |
Gross Unrealized Losses | 0 |
Total Fair Value | $ 26,573 |
Fair Value Measurements - Sch_2
Fair Value Measurements - Schedule of Contractual Maturities of Available-for-sale Debt Securities (Details) $ in Thousands | Dec. 31, 2020USD ($) |
Fair Value Disclosures [Abstract] | |
Due within one year | $ 26,573 |
One to two years | 0 |
Total | $ 26,573 |
Indebtedness - Additional Infor
Indebtedness - Additional Information (Details) | May 21, 2020USD ($)day$ / shares | May 02, 2019USD ($)Tranche | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Dec. 31, 2018USD ($) |
Debt Instrument [Line Items] | |||||
Amount funded | $ 0 | $ 28,222,000 | $ 0 | ||
Proceeds from issuance of convertible senior notes, net | 193,596,000 | $ 0 | $ 0 | ||
Term Loan | Credit Facility | |||||
Debt Instrument [Line Items] | |||||
Maximum borrowing capacity | $ 150,000,000 | ||||
Amount funded | 30,000,000 | ||||
Remaining borrowing capacity | $ 120,000,000 | ||||
Number of additional tranches | Tranche | 2 | ||||
Percentage of exit fee on amount borrowed on final repayment | 1.75% | ||||
Percentage of exit fee on amount borrowed on partial prepayment | 1.75% | ||||
Debt covenant minimum unrestricted cash percentage | 25.00% | ||||
Debt instrument, default trigger amount | $ 2,500,000 | ||||
Term Loan | Prepayment Occurs through First Anniversary of Closing Date | Credit Facility | |||||
Debt Instrument [Line Items] | |||||
Percentage of prepayment fee | 3.00% | ||||
Term Loan | First Anniversary of Closing Date through Second Anniversary of Closing Date | Credit Facility | |||||
Debt Instrument [Line Items] | |||||
Percentage of prepayment fee | 2.00% | ||||
Term Loan | Second Anniversary of Closing Date and Prior to January 1, 2025 | Credit Facility | |||||
Debt Instrument [Line Items] | |||||
Percentage of prepayment fee | 1.00% | ||||
Term Loan | LIBOR | Credit Facility | |||||
Debt Instrument [Line Items] | |||||
Basis spread on variable rate | 7.00% | ||||
Interest rate | 2.00% | ||||
Term Loan | MidCap Financial Trust | Credit Facility | |||||
Debt Instrument [Line Items] | |||||
Basis spread on variable rate | 3.00% | ||||
Term Loan | Tranche One | Credit Facility | |||||
Debt Instrument [Line Items] | |||||
Remaining borrowing capacity | $ 60,000,000 | ||||
Term Loan | Tranche Two | Credit Facility | |||||
Debt Instrument [Line Items] | |||||
Remaining borrowing capacity | $ 60,000,000 | ||||
2027 Notes | |||||
Debt Instrument [Line Items] | |||||
Interest rate | 5.00% | ||||
Debt instrument aggregate principal amount | $ 200,000,000 | ||||
Proceeds from issuance of convertible senior notes, net | $ 193,600,000 | ||||
Debt instrument, convertible, conversion ratio | 0.0616 | ||||
Debt instrument, conversion price (in dollars per share) | $ / shares | $ 16.23 | ||||
Debt instrument, conversion price (in percentage) | 130.00% | ||||
Debt conversion, converted instrument, amount | $ 1,000 | ||||
Debt instrument, redemption price (in percentage) | 100.00% | ||||
Percentage of repurchase price is equal to principal amount of convertible notes | 100.00% | ||||
Long-term debt, percentage in aggregate principal amount | 0.25 | ||||
Debt instrument, convertible, carrying amount of equity component | $ 53,500,000 | ||||
Effective interest rate | 11.17% | ||||
Debt issuance costs | $ 400,000 | ||||
Amortization of debt issuance cost | $ 300,000 | ||||
2027 Notes | Minimum | One Hundred Thirty Percent Applicable Conversion Price | |||||
Debt Instrument [Line Items] | |||||
Debt instrument, convertible, threshold trading days | day | 20 | ||||
2027 Notes | Minimum | Ninety Eight Percent Applicable Conversion Price | |||||
Debt Instrument [Line Items] | |||||
Debt instrument, convertible, threshold trading days | day | 5 | ||||
2027 Notes | Maximum | |||||
Debt Instrument [Line Items] | |||||
Debt instrument convertible conversion last reported sale price (in percentage) | 98.00% | ||||
2027 Notes | Maximum | One Hundred Thirty Percent Applicable Conversion Price | |||||
Debt Instrument [Line Items] | |||||
Debt instrument, convertible, threshold trading days | day | 30 | ||||
2027 Notes | Maximum | Ninety Eight Percent Applicable Conversion Price | |||||
Debt Instrument [Line Items] | |||||
Debt instrument, convertible, threshold trading days | day | 10 |
Indebtedness - Schedule of Long
Indebtedness - Schedule of Long-term Debt (Details) - Credit Facility $ in Thousands | Dec. 31, 2020USD ($) |
Debt Instrument [Line Items] | |
Term loan | $ 30,000 |
Debt discount and issuance costs | (1,256) |
Long-term debt | $ 28,744 |
Indebtedness - Schedule of Futu
Indebtedness - Schedule of Future Minimum Principal Payments (Details) - Credit Facility $ in Thousands | Dec. 31, 2020USD ($) |
Debt Instrument [Line Items] | |
2021 | $ 0 |
2022 | 5,806 |
2023 | 11,613 |
2024 | 11,613 |
2025 | 968 |
Total | $ 30,000 |
Indebtedness - Schedule of Net
Indebtedness - Schedule of Net Carrying Amount of Liability Component (Details) - 2027 Notes - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Debt Instrument [Line Items] | ||
Principal amount | $ 200,000 | $ 0 |
Unamortized debt discount | (56,080) | 0 |
Unamortized debt issuance cost | (278) | 0 |
Long-term debt | $ 143,642 | $ 0 |
Indebtedness - Schedule of Equi
Indebtedness - Schedule of Equity Components (Details) - 2027 Notes - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Debt Instrument [Line Items] | ||
Debt discount related to the value of conversion option | $ 53,635 | $ 0 |
Debt issuance cost | (109) | 0 |
Net carrying amount | $ 53,526 | $ 0 |
Indebtedness - Schedule of Inte
Indebtedness - Schedule of Interest Expense Recognized (Details) - 2027 Notes - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Debt Instrument [Line Items] | |||
Contractual interest expense | $ 6,139 | $ 0 | $ 0 |
Amortization of debt discount | 3,555 | 0 | 0 |
Amortization of debt issuance cost | 17 | 0 | 0 |
Total interest expense related to the 2027 Notes | $ 9,711 | $ 0 | $ 0 |
License and Asset Acquisition_2
License and Asset Acquisitions - Additional Information (Details) - USD ($) | May 11, 2020 | Sep. 21, 2018 | Jun. 24, 2018 | Jan. 04, 2018 | Oct. 02, 2017 | May 31, 2019 | Sep. 30, 2018 | Oct. 31, 2017 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Business Acquisition [Line Items] | |||||||||||
In process research and development | $ 23,380,000 | $ 3,600,000 | $ 49,659,000 | ||||||||
Seralutinib | |||||||||||
Business Acquisition [Line Items] | |||||||||||
In process research and development | 5,000,000 | 0 | 0 | ||||||||
GB001 | |||||||||||
Business Acquisition [Line Items] | |||||||||||
In process research and development | 0 | 0 | 19,148,000 | ||||||||
GB004 | |||||||||||
Business Acquisition [Line Items] | |||||||||||
In process research and development | 15,000,000 | 0 | 20,000,000 | ||||||||
GB1275 | |||||||||||
Business Acquisition [Line Items] | |||||||||||
In process research and development | 0 | $ 1,000,000 | $ 7,501,000 | ||||||||
Pulmokine, Inc. | License Agreement | Seralutinib | |||||||||||
Business Acquisition [Line Items] | |||||||||||
Product license term | 10 years | ||||||||||
Upfront payment | $ 5,500,000 | ||||||||||
Milestones accrued | 5,000,000 | ||||||||||
Pulmokine, Inc. | License Agreement | Seralutinib | Maximum | |||||||||||
Business Acquisition [Line Items] | |||||||||||
Development and regulatory milestone payments, payable | $ 58,000,000 | ||||||||||
Commercial milestone payments, payable | 45,000,000 | ||||||||||
Sales milestone payments, payable | $ 190,000,000 | ||||||||||
AA Biopharma Inc. | GB001 | |||||||||||
Business Acquisition [Line Items] | |||||||||||
In process research and development | $ 19,300,000 | ||||||||||
AA Biopharma Inc. | GB001 | Common stock | |||||||||||
Business Acquisition [Line Items] | |||||||||||
Business acquisition, aggregate number of shares issued | 1,101,278 | ||||||||||
AA Biopharma Inc. | GB001 | Series Seed convertible preferred stock | |||||||||||
Business Acquisition [Line Items] | |||||||||||
Business acquisition, aggregate number of shares issued | 20,000,000 | ||||||||||
Aerpio Pharmaceuticals, Inc. | License Agreement | GB004 | |||||||||||
Business Acquisition [Line Items] | |||||||||||
Upfront payment | $ 15,000,000 | ||||||||||
Milestones accrued | 0 | ||||||||||
Upfront payment, purchase consideration paid | $ 20,000,000 | ||||||||||
Participation right (in percentage) | 20.00% | ||||||||||
Aerpio Pharmaceuticals, Inc. | License Agreement | GB004 | Maximum | |||||||||||
Business Acquisition [Line Items] | |||||||||||
Development and regulatory milestone payments, payable | 40,000,000 | ||||||||||
Sales milestone payments, payable | $ 50,000,000 | ||||||||||
Adhaere Pharmaceuticals, Inc. | GB1275 | |||||||||||
Business Acquisition [Line Items] | |||||||||||
Milestones accrued | $ 0 | ||||||||||
In process research and development | $ 7,500,000 | ||||||||||
Upfront payment, purchase consideration paid | $ 7,500,000 | ||||||||||
Milestones payment | $ 1,000,000 | ||||||||||
Adhaere Pharmaceuticals, Inc. | GB1275 | Maximum | |||||||||||
Business Acquisition [Line Items] | |||||||||||
Regulatory, development and sales milestone payments payable | $ 62,000,000 |
License and Asset Acquisition_3
License and Asset Acquisitions - Schedule of IPR&D Expense (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total in process research and development | $ 23,380 | $ 3,600 | $ 49,659 |
Seralutinib | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total in process research and development | 5,000 | 0 | 0 |
GB004 | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total in process research and development | 15,000 | 0 | 20,000 |
GB1275 | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total in process research and development | 0 | 1,000 | 7,501 |
GB001 | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total in process research and development | 0 | 0 | 19,148 |
Other preclinical programs | |||
Acquired Finite-Lived Intangible Assets [Line Items] | |||
Total in process research and development | $ 3,380 | $ 2,600 | $ 3,010 |
Income Taxes - Schedule of Amou
Income Taxes - Schedule of Amount of Net Loss Before Taxes (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |||
U.S. loss before taxes | $ 186,888 | $ 138,342 | $ 116,920 |
Foreign loss before taxes | 56,472 | 41,965 | 30,049 |
Loss before income taxes | $ 243,360 | $ 180,307 | $ 146,969 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Detail) - USD ($) $ in Millions | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2018 | |
Operating Loss Carryforwards [Line Items] | ||
Increase (decrease) in valuation allowance | $ 38.9 | |
Decrease in deferred tax asset | $ 0.8 | |
Unrecognized tax benefits that would not impact effective tax rate | 5.1 | |
Orphan Drug Credit | ||
Operating Loss Carryforwards [Line Items] | ||
Research and development credit | $ 17.9 | |
Maximum | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating losses carryforward available to offset future federal taxable income , percentage | 80.00% | |
Federal | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating losses (“NOL”) carryforwards | $ 310.7 | |
Net operating losses (“NOL”) that can be carried forward indefinitely | 307.7 | |
Research and development credit | 17.9 | |
California | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating losses (“NOL”) carryforwards | 1.1 | |
Research and development credit | 5.4 | |
Foreign Tax Authority | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating losses (“NOL”) carryforwards | $ 101.1 |
Income Taxes - Schedule of Defe
Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Deferred tax assets: | |||
Net operating losses | $ 77,946 | $ 43,626 | $ 14,442 |
Tax credits, net | 17,372 | 9,196 | 1,131 |
Amortization | 10,939 | 6,597 | 6,267 |
Stock-based compensation | 4,448 | 1,388 | 0 |
Lease liability | 2,383 | 2,329 | 0 |
Accrued compensation | 2,137 | 1,476 | 834 |
Other | 16 | 383 | 154 |
Total gross deferred tax assets | 115,241 | 64,995 | 22,828 |
Deferred tax liabilities: | |||
Convertible senior notes | (10,592) | 0 | 0 |
Right of use asset | (2,215) | (2,164) | 0 |
Property, plant and equipment | (776) | (57) | (16) |
Stock-based compensation | 0 | 0 | (1,057) |
Total gross deferred tax liabilities | (13,583) | (2,221) | (1,073) |
Valuation allowance | (101,658) | (62,774) | (21,755) |
Net deferred tax asset | $ 0 | $ 0 | $ 0 |
Income Taxes - Reconciliation o
Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Detail) | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income Tax Disclosure [Abstract] | |||
Federal statutory income tax rate | 21.00% | 21.00% | 21.00% |
State income taxes, net of federal benefit | 0.00% | 0.00% | 0.00% |
Change in valuation allowance | (19.50%) | (22.12%) | (13.17%) |
Research and experimentation credits | 2.76% | 3.81% | 0.77% |
Foreign rate differential | (1.64%) | (1.84%) | (1.74%) |
Stock-based compensation | (1.81%) | 0.00% | (2.60%) |
In process research and development | 0.00% | 0.00% | (3.92%) |
Other | (0.80%) | (0.85%) | (0.34%) |
Provision for income taxes | 0.00% | 0.00% | 0.00% |
Income Taxes - Schedule of Reco
Income Taxes - Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits, Excluding Interest and Penalties (Detail) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | |||
Balance at beginning of the year | $ 2,754 | $ 408 | $ 0 |
Increase related to current year positions | 2,306 | 2,346 | 408 |
Balance at the end of the year | $ 5,060 | $ 2,754 | $ 408 |
Stockholders' Equity (Deficit)
Stockholders' Equity (Deficit) - Additional Information (Details) | May 21, 2020USD ($)$ / sharesshares | Sep. 06, 2018$ / sharesshares | May 21, 2018$ / sharesshares | Jan. 04, 2018 | Dec. 03, 2015USD ($)$ / sharesshares | Nov. 30, 2017shares | Mar. 31, 2019shares | Dec. 31, 2020USD ($)voteshares | Dec. 31, 2019USD ($)shares | Dec. 31, 2018USD ($)shares |
Stockholders Equity Deficit [Line Items] | ||||||||||
Common stock, voting right per share | vote | 1 | |||||||||
Sale of shares of common stock (in shares) | 9,433,963 | |||||||||
Offering price (in dollars per share) | $ / shares | $ 13.25 | |||||||||
Proceeds from issuance of common stock | $ | $ 117,100,000 | $ 117,110,000 | $ 291,311,000 | $ 0 | ||||||
Issuance of common stock in connection with a public offering, net of underwriting discounts, commissions, and offering costs | $ | $ 117,094,000 | $ 291,311,000 | ||||||||
Shares of common stock, repurchase (in shares) | 1,649,348 | 4,648,526 | 7,482,032 | |||||||
Stock Restriction Agreements | ||||||||||
Stockholders Equity Deficit [Line Items] | ||||||||||
Shares subject to forfeiture (in shares) | 441,801 | |||||||||
Founder | ||||||||||
Stockholders Equity Deficit [Line Items] | ||||||||||
Sale of shares of common stock (in shares) | 1,795,023 | 251,547 | ||||||||
Issuance price per share (in dollars per share) | $ / shares | $ 9.63 | $ 2.61 | ||||||||
Percentage of fully diluted share capital | 15.00% | |||||||||
Increased in equity capital amount | $ | $ 300,000,000 | |||||||||
Additional shares of restricted stock subject to vesting restrictions (in shares) | 1,795,023 | 251,547 | ||||||||
Common stock | ||||||||||
Stockholders Equity Deficit [Line Items] | ||||||||||
Conversion of convertible preferred stock into common stock (in shares) | 30,493,460 | 30,493,460 | ||||||||
Sale of shares of common stock (in shares) | 9,433,963 | 19,837,500 | ||||||||
Issuance of common stock in connection with a public offering, net of underwriting discounts, commissions, and offering costs | $ | $ 1,000 | $ 2,000 | ||||||||
Founder Shares | ||||||||||
Stockholders Equity Deficit [Line Items] | ||||||||||
Sale of shares of common stock (in shares) | 9,160,888 | |||||||||
Issuance price per share (in dollars per share) | $ / shares | $ 0.0001 | |||||||||
Issuance of common stock in connection with a public offering, net of underwriting discounts, commissions, and offering costs | $ | $ 4,100 | |||||||||
Common Stock vesting percentage | 50.00% | |||||||||
Common stock vesting period | 5 years | |||||||||
Series A convertible preferred stock | Stock Restriction Agreements | ||||||||||
Stockholders Equity Deficit [Line Items] | ||||||||||
Shares subject to forfeiture (in shares) | 1,305,421 |
Equity Incentive Plans - Additi
Equity Incentive Plans - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | Feb. 06, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Shares outstanding awarded (in shares) | 9,401,082 | 8,538,060 | 5,107,329 | 0 | |
Expected dividends yield (in percentage) | 0.00% | ||||
Total stock-based compensation | $ 38,748 | $ 20,819 | $ 30,947 | ||
Restricted Stock | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Unrecognized compensation, recognition period | 1 year 10 months 24 days | ||||
Unrecognized compensation related to unvested restricted stock awards | $ 18,800 | ||||
Restricted Stock | Chief Executive Officer | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Total stock-based compensation | $ 5,500 | ||||
Stock Options | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Expected dividends yield (in percentage) | 0.00% | 0.00% | 0.00% | ||
Weighted-average grant date fair value (in dollars per share) | $ 9.82 | $ 13.17 | $ 4.87 | ||
Aggregate fair value of stock options vested | $ 29,900 | $ 7,200 | $ 100 | ||
Aggregate intrinsic value, options vested in period | 1,100 | $ 6,900 | $ 0 | ||
Unrecognized compensation related to unvested stock option | $ 48,100 | ||||
Unrecognized compensation, recognition period | 2 years 4 months 24 days | ||||
2019 Equity Incentive Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Number of share reserved for future issuance (in shares) | 5,750,000 | ||||
Term of awards | 10 years | ||||
Percentage of amount increase in outstanding shares | 5.00% | ||||
Common stock available for issuance (in shares) | 1,609,830 | ||||
Shares reserved for issuance on granting of outstanding awards (in shares) | 7,140,993 | ||||
2019 Employee Stock Purchase Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Number of share reserved for future issuance (in shares) | 700,000 | ||||
Percentage of amount increase in outstanding shares | 1.00% | ||||
Number of shares issued under ESPP plan | 113,286 | ||||
Number of share reserved for future issuance (in shares) | 1,249,554 | ||||
2019 Employee Stock Purchase Plan | Stock-Based Compensation Expense | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Unrecognized compensation related to unvested stock option | $ 1,400 | ||||
Unrecognized compensation, recognition period | 1 year | ||||
2019 Employee Stock Purchase Plan | Maximum | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Purchase of common stock through payroll deductions, percentage | 20.00% | ||||
2017 Equity Incentive Plan | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Shares outstanding awarded (in shares) | 3,941,562 | ||||
2017 Equity Incentive Plan | Restricted Stock | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||||
Stock awards granted (in shares) | 268,719 |
Equity Incentive Plans - Schedu
Equity Incentive Plans - Schedule of Fair Value Assumptions Stock Options (Details) | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected dividends yield (in percentage) | 0.00% | ||
Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Risk-free interest rate, minimum | 0.22% | 1.38% | 2.65% |
Risk-free interest rate, maximum | 1.67% | 2.58% | 2.96% |
Volatility, minimum | 84.38% | 70.25% | 69.13% |
Volatility, maximum | 87.23% | 86.92% | 77.62% |
Expected dividends yield (in percentage) | 0.00% | 0.00% | 0.00% |
ESPP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Risk-free interest rate, minimum | 0.12% | 1.46% | |
Risk-free interest rate, maximum | 0.95% | 1.87% | |
Volatility, minimum | 85.50% | 72.08% | |
Volatility, maximum | 99.13% | 78.70% | |
Expected dividends yield (in percentage) | 0.00% | 0.00% | |
Minimum | Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted-average expected life (in years) | 4 years 7 months 6 days | 4 years 7 months 6 days | 5 years 3 months 18 days |
Minimum | ESPP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted-average expected life (in years) | 5 months 26 days | 5 months 26 days | |
Maximum | Stock Options | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted-average expected life (in years) | 6 years 1 month 6 days | 6 years 1 month 6 days | 6 years 1 month 6 days |
Maximum | ESPP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Weighted-average expected life (in years) | 2 years | 1 year 11 months 26 days |
Equity Incentive Plans - Summar
Equity Incentive Plans - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] | ||||
Shares Subject to Options Outstanding, Beginning (in shares) | 8,538,060 | 5,107,329 | 0 | |
Shares Subject to Options Outstanding, Options granted (in shares) | 2,712,372 | 4,194,624 | 5,143,551 | |
Shares Subject to Options Outstanding, Option exercised (in shares) | (134,803) | (419,593) | 0 | |
Shares Subject to Options Outstanding, Options forfeited/cancelled (in shares) | (1,714,547) | (344,300) | (36,222) | |
Shares Subject to Options Outstanding, Ending (in shares) | 9,401,082 | 8,538,060 | 5,107,329 | 0 |
Shares Subject to Options Outstanding, Options vested and exercisable as of December 31,2020 (in shares) | 3,749,170 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] | ||||
Weighted-Average Exercise Price, Outstanding, beginning (in dollars per share) | $ 13.67 | $ 7.51 | $ 0 | |
Weighted-Average Exercise Price, Options granted (in dollars per share) | 13.78 | 20.11 | 7.49 | |
Weighted-Average Exercise Price, Option exercised (in dollars per share) | 3.96 | 4.87 | 0 | |
Weighted-Average Exercise Price, Options forfeited/cancelled (in dollars per share) | 15.99 | 11.64 | 4.85 | |
Weighted-Average Exercise Price, Outstanding, ending (in dollars per share) | 13.42 | $ 13.67 | $ 7.51 | $ 0 |
Weighted-Average Exercise Price, Options vested and exercisable as of December 31, 2020 (in dollars per share) | $ 12.66 | |||
Weighted-Average Remaining Contractual Life (Years), Outstanding | 8 years 1 month 6 days | 9 years | 9 years 8 months 12 days | 0 years |
Weighted-Average Remaining Contractual Life (Years), Options vested and exercisable | 7 years 6 months | |||
Aggregate Intrinsic Value, Outstanding | $ 10,182 | $ 35,385 | $ 16,343 | $ 0 |
Aggregate Intrinsic Value, Options vested and exercisable | $ 6,293 |
Equity Incentive Plans - Summ_2
Equity Incentive Plans - Summary of Restricted Stock Activity (Details) - Restricted Stock - $ / shares | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | |||
Number of Restricted Stock Units Outstanding, Nonvested, beginning (in shares) | 4,648,526 | 7,482,032 | 1,305,421 |
Number of Restricted Stock Units Outstanding, Granted (in shares) | 2,003,900 | 0 | 8,673,584 |
Number of Restricted Stock Units Outstanding, Vested (in shares) | (2,557,377) | (2,833,506) | (2,369,696) |
Number of Restricted Stock Units Outstanding, Forfeited (in shares) | (764,228) | 0 | (127,277) |
Number of Restricted Stock Units Outstanding, Nonvested, ending (in shares) | 3,330,821 | 4,648,526 | 7,482,032 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | |||
Weighted-Average Grant Date Fair Value, Nonvested (in dollars per share) | $ 3.98 | $ 4.01 | $ 0.09 |
Weighted-Average Grant Date Fair Value, Granted (in dollars per share) | 10.96 | 0 | 5.53 |
Weighted-Average Grant Date Fair Value, Vested (in dollars per share) | 4 | 4.05 | 7.58 |
Weighted-Average Grant Date Fair Value, Forfeited (in dollars per share) | 8.30 | 0 | 0.09 |
Weighted-Average Grant Date Fair Value, Nonvested (in dollars per share) | $ 7.16 | $ 3.98 | $ 4.01 |
Equity Incentive Plans - Stock-
Equity Incentive Plans - Stock-Based Compensation Expense Reported in Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Incremental stock compensation expense | $ 38,748 | $ 20,819 | $ 30,947 |
Research and development | |||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Incremental stock compensation expense | 18,997 | 10,227 | 679 |
General and administrative | |||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | |||
Incremental stock compensation expense | $ 19,751 | $ 10,592 | $ 30,268 |
Property and Equipment, Net - S
Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Property, Plant and Equipment [Line Items] | ||
Total property and equipment | $ 8,157 | $ 6,639 |
Less: accumulated depreciation | 2,623 | 1,214 |
Property and equipment, net | 5,534 | 5,425 |
Office equipment | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment | $ 1,153 | 1,097 |
Office equipment | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, estimated useful life | 3 years | |
Office equipment | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, estimated useful life | 7 years | |
Computer equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, estimated useful life | 5 years | |
Total property and equipment | $ 123 | 124 |
Software | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, estimated useful life | 3 years | |
Total property and equipment | $ 116 | 87 |
Lab equipment | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment | $ 4,210 | 3,054 |
Lab equipment | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, estimated useful life | 2 years | |
Lab equipment | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, estimated useful life | 5 years | |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment | $ 2,540 | 2,229 |
Leasehold improvements | Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, estimated useful life | 6 years | |
Leasehold improvements | Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, estimated useful life | 7 years | |
Construction in process | ||
Property, Plant and Equipment [Line Items] | ||
Total property and equipment | $ 15 | $ 48 |
Property and Equipment, Net - A
Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Property, Plant and Equipment [Abstract] | |||
Depreciation expense | $ 1.4 | $ 0.9 | $ 0.3 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Details) - USD ($) | Jul. 29, 2020 | Jun. 30, 2020 | Nov. 30, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Lessee, Lease, Description [Line Items] | ||||||
Weighted average discount rate, operating leases | 7.00% | |||||
Weighted average remaining lease term | 3 years 4 months 24 days | |||||
Cash paid for operating lease liabilities | $ 3,600,000 | $ 3,000,000 | ||||
Rent expense | $ 4,000,000 | $ 3,100,000 | ||||
Rent expense | $ 1,500,000 | |||||
Non-cancelable Lease Agreement Entered in August 2018 | ||||||
Lessee, Lease, Description [Line Items] | ||||||
Operating sublease, annual increase percentage for base rent | 3.00% | |||||
Additional Non-cancelable Lease Agreement In Nov 2019 | ||||||
Lessee, Lease, Description [Line Items] | ||||||
Monthly base rent for permanent space | $ 63,425 | |||||
Monthly base rent for temporary space | $ 28,745 | |||||
Extended lease term of permanent space | 12 months | |||||
Annual increase percentage for lease charges | 3.00% | |||||
Sublease Agreement Entered in June 2020 | ||||||
Lessee, Lease, Description [Line Items] | ||||||
Sublease temporary monthly base rent | $ 63,425 | |||||
Weighted average discount rate, operating leases | 3.00% | |||||
Weighted average remaining lease term | 6 months | |||||
Sublease Income | $ 200,000 | |||||
Lease Assignment Agreement Entered in July 2020 | ||||||
Lessee, Lease, Description [Line Items] | ||||||
Annual increase percentage for lease charges | 2.50% | |||||
Operating lease, renewal term | 5 years | |||||
Monthly base rent expense | $ 28,495 |
Commitments and Contingencies_2
Commitments and Contingencies - Schedule of Lease Costs (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2020USD ($) | |
Leases [Abstract] | |
Operating lease cost | $ 3,615 |
Short-term lease cost | 78 |
Total lease cost | $ 3,693 |
Commitments and Contingencies_3
Commitments and Contingencies - Schedule of Gross Future Minimum Annual Rental Commitments (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Leases [Abstract] | ||
2021 | $ 4,273 | |
2022 | 3,579 | |
2023 | 2,063 | |
2024 | 2,123 | |
2025 | 387 | |
Thereafter | 397 | |
Total undiscounted rent payments | 12,822 | |
Present value discount | (1,476) | |
Present value | 11,346 | |
Operating lease liabilities, current | 3,633 | $ 2,354 |
Operating lease liabilities - long-term | 7,713 | $ 8,737 |
Total operating lease liability | $ 11,346 |